

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |  |   |
|--|--|--|---|
| (51) International Patent Classification <sup>7</sup> :<br>C12N 15/86, 7/01, 5/10, A61K 39/00,<br>39/145, 48/00  |  | A1   | (11) International Publication Number: <b>WO 00/53786</b>         |
|  |  |  | (43) International Publication Date: 14 September 2000 (14.09.00) |
| (21) International Application Number: PCT/EP00/01903  |  | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |   |
| (22) International Filing Date: 3 March 2000 (03.03.00)  |  |  |   |
| (30) Priority Data:<br>99104519.6 6 March 1999 (06.03.99) EP   |  |  |   |
| (71) Applicant (for all designated States except US): ARTEMIS PHARMACEUTICALS GMBH (DE/DE); Neurather Ring 1, D-51063 Köln (DE).   |  |  |   |
| (72) Inventors; and<br>(73) Inventors/Applicants (for US only): HOBOM, Gerd (DE/DE); Arndtstrasse 14, D-35392 Giessen (DE); FLICK, Ramon (DE/SE); Lilla Hallstravägen 28, S-137 93 Västerhaninge (SE); MENKE, Anette (DE/DE); Ockershäuser Allee 7, D-35037 Marburg (DE); AZZEH, Maysa (IL/DE); Altentfeldsweg 32, D-35394 Giessen (DE). |  | Published<br>With international search report.<br>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.   |   |
| (74) Agents: HIEBING, Jörg et al.; Von Kreistler Selting Werner, Deichmannhaus am Dom, D-50667 Köln (DE).  |  |  |   |

(54) Title: STABLE RECOMBINANT INFLUENZA VIRUSES FREE OF HELPER VIRUSES

(57) Abstract

The invention relates to a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus and which comprises at least one viral RNA segment being an ambisense RNA molecule (ambisense RNA segment) and containing one of the standard viral genes in sense orientation and a foreign, recombinant gene in anti-sense orientation, or vice versa, in overall convergent arrangement. The present invention further provides a method for the production of said recombinant influenza virus, a method for constructing specific ribozyme-sensitive influenza carrier strains; pharmaceutical compositions comprising said recombinant influenza virus, and the use of said recombinant influenza virus for preparing medicaments for vaccination purposes.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NI | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

## **Stable Recombinant Influenza Viruses Free of Helper Viruses**

### **5 Field of the Invention**

The invention relates to a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus; a method for the production of said recombinant influenza virus, a method for constructing specific ribozyme-sensitive influenza carrier strains; pharmaceutical compositions comprising  
10 said recombinant influenza viruses; and the use of said recombinant influenza virus for preparing medicaments for vaccination purposes.

### **Technical Background**

15 Redesigning influenza virus into a vector system for expression of foreign genes similar to what has been achieved in several other thoroughly studied viruses such as adenovirus, retrovirus, Semliki Forest virus or Rabies virus has the advantage of an industrially well established mode of cheap propagation for influenza in fertilized chicken eggs leading to rather  
20 high titers (above  $10^{10}$ /ml). On the other hand none of its genes may be deleted from the influenza genome according to our present knowledge, and give room for large-size foreign insertions. Only small fragments of foreign polypeptide chains such as B cell epitopes (10 to 15 amino acids) may be inserted into selected positions within two of the viral proteins, i.e.  
25 in exchange for one of the variable antigenic regions located at the surface of hemagglutinin (Muster et al., Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69 (11), 6678-6686 (1995)), or into the stalk sequence of viral neuraminidase (Garcia-Sastre and Palese, The cytoplasmic tail of the  
30 neuraminidase protein of influenza A virus does not play an important role in the packaging of this protein into viral envelopes. Virus Res. 37, 37-47 (1995)), and be stably maintained as functional fusion proteins.

Constructs of this kind turned out to be useful for experimental vaccination in a few cases studied, but only rather few clearly defined epitope sequences (of ten to twelve amino acids each) are known today, and some of them might also be misfolded within such restricted fusion  
5 protein positions, or in other cases interfere with the correct tertiary structure and function of their host polypeptide chains.

Incorporation of a full-size foreign protein into influenza via reverse genetics, encoded by an independent ninth vRNA molecule in addition to its regular set of eight standard vRNA segments is without special  
10 provisions only transiently possible (Luytjes et al., Amplification, expression, and packaging of a foreign gene by influenza virus. Cell 59, 1107-1113 (1989); Enami et al., An influenza virus containing nine different RNA segments. Virology 185, 291-298 (1991)). In the absence of a continuous selective pressure any additional recombinant vRNA segment  
15 cannot be stably maintained as long as a wildtype promoter sequence is used on that ninth vRNA segment, and it will inadvertently be lost after few steps of propagation.

Using a different system of influenza reverse genetics developed in our laboratory (Zobel et al., RNA polymerase I catalysed transcription of insert  
20 viral cDNA. Nucleic Acids Res. 21, 3607-3614 (1993); Neumann et al., RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 202, 477-479 (1994)), which was built around *in vivo* synthesis of recombinant vRNA molecules by cellular RNA polymerase I transcription of the respective template cDNA constructs, promoter-up mutations have  
25 been designed by nucleotide substitutions (Neumann and Hobom, Mutational analysis of influenza virus promoter elements *in vivo*. J. Gen. Virol. 76, 1709-1717 (1995)). When these are attached to a recombinant ninth vRNA segment its increased transcription and amplification rate will not only compensate for the losses suffered spontaneously, but even  
30 cause accumulation of the foreign vRNA segment during simple viral passaging, in the absence of any selection. However, due to its over-replication relative to all of the regular influenza vRNA segments (which of

course are connected to wild-type promoter sequences) after catching up with the others the foreign segment will become over-abundant. This increasingly will result in viral particles that have incorporated several copies of recombinant vRNA, but no longer have a full set of all eight standard segments incorporated among an average of about 15 vRNA molecules present within a virion. Such particles are defective and will not result in plaque formation, hence after an initial increase of recombinant viral particles during the first steps of propagation a dramatic decrease is observed, usually at the third or fourth step of viral passaging, depending on the size of the recombinant vRNA and the level of the promoter-up mutation attached. A balanced situation with regard to the insert length and the level of promoter activity can be achieved, and has been propagated in a particular case over 11 passages, with essentially stable levels of recombinant viruses among a majority of helper viruses (around 80%) during these steps. If a full-level promoter-up mutation is used (1104 or the new variant 1920, see below) a balanced-level propagation is reached in conjunction with a recombinant vRNA size of 4000 nucleotides (Maysa Azzeh, Ph.D. Thesis, Univ. Giessen (2000)).

In all of these preparations, both in transiently achieved increased yields (up to 40% of recombinants after three or four steps of viral passage), and in a balanced propagation of recombinant influenza viruses (10 - 20%) the respective viral progeny inadvertently constitute mixtures with a majority of non-recombinant helper viruses. These result both from a statistical mode of packaging vRNA molecules into a virion (the ninth segment may not be co-packaged), and from the fraction of cells solely infected by helper virus.

The problems of fractional yields and of instability during viral propagation of recombinant influenza are the problems to be solved with the present invention.

30

### Summary of the Invention

Starting out from two observations in this laboratory which are discussed below and which concern two hitherto unsuspected properties of influenza viral RNA polymerase in its interaction with terminally adapted influenza-specific RNA molecules, a new technique for the construction of stable recombinant influenza viruses was found.

As previously described in WO 96/10641 plasmid constructs are designed to generate influenza vRNA-like molecules *in vivo* by cellular RNA polymerase I transcription following plasmid DNA transfection into tissue culture cells, and to this end contain flanking rDNA promoter and terminator elements, externally located relative to any cDNA constructs in between. The resulting recombinant vRNA molecules are designed to contain 5' and 3' recognition sequences for influenza viral RNA polymerase, which however carry up to five nucleotide substitutions (in promoter-up mutant pHL1920) resulting in a substantial increase of expression over wildtype influenza promoter levels. While recombinant pseudoviral RNA is initially transcribed by RNA polymerase I, further amplification and mRNA transcription depends on the presence of viral RNA polymerase and viral nucleoprotein in the cell, which generally are provided by infection of a helper virus. As a consequence the progeny viral yield will constitute a mixture of recombinant viruses together with a majority of wild-type helper viruses.

In the new technique the recombinant vRNA-like molecules as transcribed by RNA polymerase I are constructed as ambisense RNA double segments, with one reading frame (an influenza gene) in sense and a second one (a foreign gene) in anti-sense orientation, or vice versa. In such constructs both reading frames will be expressed via the cap-snatching mode, even if at different levels. Again, infection by helper virus is required to provide the necessary viral early and late proteins for genetic expression and virion packaging. However, the particular helper virus used in the new method is a recombinant virus carrying 2x2 specifically designed ribozyme targets inserted into the flanking non-coding sequences of one of its eight

vRNA segments. The viral segment chosen to become ribozyme-sensitive is always identical to the one used in constructing the recombinant ambisense RNA molecule, as the viral carrier gene in covalent linkage with an additional foreign gene.

- 5 Recombinant influenza viruses produced in this way through RNA polymerase I transcription of an ambisense viral RNA molecule followed by infection with that specifically designed type of ribozyme-sensitive helper virus will carry one of the influenza genes twice, once within that ribozyme-sensitive helper vRNA segment, and a second time within the
- 10 ribozyme-resistant ambisense segment. Recombinant viruses of this type are again obtained initially only as a mixture together with a majority of non-recombinant helper viruses. A progeny viral passage through tissue culture cells (293T) which before have been transiently transfected with plasmid constructs expressing the respective double-headed ribozyme will
- 15 (in one step) inactivate the ribozyme-sensitive segment by a factor of up to 100. One or two rounds of such ribozyme treatment *in vivo* will at the same time (a) purify the recombinant virus from its non-recombinant helper contaminants, and (b) delete the sensitive vRNA helper segment from within the initial (additive) recombinant virus.
- 20 As a result recombinant influenza viruses are isolated along this several-step procedure, which are free of contaminating helper viruses and carry seven regular and one ambisense vRNA segments, all in a balanced replication mode. Their recombinant nature is stably maintained because of a covalent junction between one of the viral genes and the full-size
- 25 foreign gene inserted, a situation achieved here for the first time, via constructing an influenza ambisense RNA segment. The whole procedure is independent of any (selectable) phenotype, and can be applied to either of the eight influenza vRNA segments. After establishing a first ambisense vRNA segment carrying a single foreign gene it can also be repeated all
- 30 over for inserting a second foreign gene within another ambisense RNA segment of the same constitution in principle.

Stable recombinant viruses of the type described can be used for cheap propagation in fertilized eggs, either for production of those recombinant viruses themselves or for production of foreign proteins or glycoproteins encoded by them, and hence find application in (glyco)protein production or in providing vector systems for somatic gene therapy or in being used as vaccination agents.

Thus, the present invention provides

- (1) a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus and which comprises at least one viral RNA segment being an ambisense RNA molecule (hereinafter "ambisense RNA segment") and containing one of the standard viral genes in sense orientation and a foreign, recombinant gene in anti-sense orientation, or *vice versa*, in overall convergent arrangement;
- (2) a preferred embodiment of the recombinant influenza virus defined in (1) above, wherein one or more of the regular viral RNA segments, differing from said at least one ambisense RNA segment (hereinafter "modified regular segment"), comprises a vRNA encoding a foreign gene, preferably one or more of the regular viral RNA segments has (have) been exchanged for a vRNA encoding a foreign gene;
- (3) a preferred embodiment of the recombinant influenza virus defined in (1) and (2) above, in which the terminal viral RNA sequences of said one or more modified regular segments and/or of said at least one ambisense RNA segment, which are active as the promoter signal, have been modified by nucleotide substitutions in up to five positions, resulting in improved transcription rates of both the vRNA promoter as well as the cRNA promoter as present in the complementary sequence;
- (4) a method for the production of recombinant influenza viruses as defined in (1) to (3) above comprising
  - (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, in antisense, sense or ambisense design,



- (b) followed by infection with an influenza carrier strain constructed to include flanking ribozyme target sequences in at least one of its viral RNA segments, and
- (c) thereafter selective vRNA inactivation through ribozyme cleavage;
- 5 (5) a method of constructing influenza carrier strains carrying one or more ribozyme target sites (of type one) in vRNA flanking positions comprising
- (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, carrying two different 3' promoter sequences in tandem, which are separated by a second type of ribozyme target sequence, and which carry the said
- 10 internal ribozyme target sites of type one;
- (b) followed by infection of an influenza wildtype strain;
- (c) thereafter amplification through simple steps of viral propagation; and
- (d) finally isolation through removal of their external 3' promoter sequence by ribozyme cleavage through infection of cells expressing
- 15 ribozyme type 2, followed by plaque purification, said method being suitable for the construction of an influenza carrier strain required for step (b) of (4) above;
- (6) a ribozyme-sensitive influenza carrier (helper) strain obtainable by the method of (5) above;
- 20 (7) a pharmaceutical composition comprising a recombinant influenza virus as defined in (1) to (3) above;
- (8) the use of a recombinant influenza virus as defined in (1) to (3) above for preparing a medicament for vaccination purposes;
- (9) the use of a recombinant influenza virus as defined in (1) to (3) above
- 25 for preparing agents for somatic gene therapy;
- (10) the use of a recombinant influenza virus as defined in (1) to (3) above for preparing agents for transfer and expression of foreign genes into cells (abortively) infected by such viruses;
- (11) the use of a recombinant influenza virus as defined in (1) to (3)
- 30 above for preparing agents for transfer and expression of RNA molecules into cells infected by such viruses;

- (12) a method for the production of proteins or glycoproteins which comprises utilizing a recombinant influenza virus as defined in (1) to (4) above as expression vector;
- (13) a method for preventing and/or treating influenza which comprises  
5 administering a recombinant influenza virus as defined in (1) to (3) above to the mammal to be treated, i.e., a vaccination method utilizing said recombinant virus;
- (14) a method for somatic gene therapy, which method comprises subjecting the organism to be treated with a recombinant influenza virus  
10 as defined in (1) to (3) above;
- (15) a method for transfer and expression of foreign genes into cells, and for transfer and expression of RNA molecules into cells, which method comprises infecting the cells with a recombinant influenza virus as defined in (1) to (3) above;
- 15 (16) use of a recombinant influenza virus as defined in (1) to (3) above for preparing agents for autologous immunotherapy;
- (17) a method for an immunotherapy which comprises *ex vivo* infection of immune cells with a recombinant influenza virus as defined in (1) to (3) above, and introduction of the transduced cells into the patient; and
- 20 (18) a method for the induction of antibodies which comprises utilizing a recombinant influenza virus as defined in (1) to (3) above as an immunogen.

### **Brief Description of the Figures**

- 25 Fig.1 shows 3' nucleotide extensions of influenza vRNA template molecules.
- Fig. 2 shows propagation of recombinant influenza viruses with tandem bicistronic vRNA.
- Fig. 3 shows tandem bicistronic vRNA supporting an alternative mode of  
30 transcription and replication initiation
- Fig. 4 shows the outgrowth of promoter-up recombinant vRNA versus wildtype vRNA segments in stepwise propagation of influenza virus.

Fig.5 shows pAM403 ribozyme cleavage of pHL2969 derived vRNA molecules at specific target sites inserted between an external and an internal 3' promoter sequence.

Fig. 6 shows comparative cleavage analysis of model CAT vRNAs with  
5 tandem target sites in various flanking positions, by target-specific ribozymes.

Fig. 7 shows an alignment of pAM424 double-headed ribozyme with one of their repetitive target sequences located within the 5' and 3' vRNA flanking regions.

10 Fig. 8 shows pAM424 ribozyme cleavage of resistant FPV wild-type HA vRNA and ribozyme-sensitive pHL2969-derived HA-vRNA in 293T cells.

Fig. 9 shows a functional analysis of the influenza cRNA promoter structure.

Fig.10 shows a functional analysis of the vRNA and cRNA promoter in  
15 ambisense arrangement.

Fig.11 shows a basepair substitution according to the vRNA 'corkscrew' structure.

Fig. 12 shows a flow-chart of the isolation procedure for an ambisense recombinant influenza virus.

20 Fig. 13 shows immuno-electron microscopy of purified influenza FPV/CSFV-E2-HA virions.

Fig. 14 shows vector pHL2969.

Fig. 15 shows vector pAM403.

Fig. 16 shows vector pAM424.

25 Fig. 17 shows vector pHL2507.

Fig. 18 shows vector pHL2583.

Fig. 19 shows vector pHL2989.

Fig. 20 shows vector pHL1920.

### 30 Detailed Description of the Invention

According to the present invention "influenza virus" embraces influenza A virus, influenza B virus and influenza C virus, with influenza A virus being

preferred. A "mammal" according to the present invention includes humans and animals. "Organism" embraces prokariotic and eukariotic systems as well as multicellular systems such as vertebrates (including mammals) and invertebrates. "Infected cells" and "infecting cells" according to the present invention also include "abortively infected cells" and "abortively infecting cells", respectively.

In a preferred influenza virus according to embodiment (1) at least one of the regular viral RNA segments is replaced by an ambisense RNA segment which contains one of the standard viral genes in sense orientation and a foreign, recombinant gene in anti-sense orientation or vice versa in overall convergent arrangement. It is moreover preferred that in the ambisense RNA molecule said foreign recombinant gene is covalently bound to one of the viral genes while the original vRNA segment coding for the same gene is deleted from the recombinant virus by a specific ribozyme cleavage.

The foreign gene(s) in ambisense covalent junction with the viral gene(s) preferably code for proteins and/or glycoproteins which are secreted from cells infected with the recombinant virus, such as lymphokines, or code for glycoproteins that are incorporated into the virion as well as the plasma membrane of the infected cell. In another preferred embodiment the foreign gene(s) in ambisense covalent junction with the viral gene(s) code for proteins or artificial polypeptides designed to support an efficient presentation of inherent epitopes at the surface of infected cells, for stimulation of B cell and/or T cell response. Such proteins or artificial polypeptides constitute for instance a tumor antigen or an artificial oligomeric series of T cell epitopes. Finally, the foreign gene(s) may be suitable for transfer and expression of RNA molecules, including antisense RNAs and double stranded RNAs, into cells. Such recombinant influenza viruses are suitable for sequence specific gene silencing, for example by antisense or RNA interference mechanisms.

A preferred recombinant virus of embodiment (2) of the invention is where in the regular viral RNA segments one or both of the standard glycoproteins hemagglutinin and neuraminidase have been exchanged, preferably into foreign glycoprotein(s) or into fusion glycoproteins consisting of an anchor segment derived from hemagglutinin and an ectodomain obtained from the foreign source, viral or cellular, or in which such recombinant glycoprotein has been inserted as a third molecular species in addition to the remaining standard components.

As set forth in embodiment (3) above, a preferred recombinant virus of the invention is where the terminal viral RNA sequences, which are active as promoter signal, have been modified by nucleotide substitution in up to 5 positions, resulting in improved transcription rates (of both the vRNA promoter and in the cRNA promoter as present in the complementary sequence) as well as enhanced replication and/or expression rates relative to the wild-type sequence. Said modified terminal viral RNA sequences differ from the wild-type sequence in that they are containing at least one segment (a naturally occurring segment or an additional segment) wherein the 12 nucleotide conserved influenza 3' terminal sequence has been modified by replacement of one to three nucleotides occurring in said sequence at positions 3, 5 and 8 relative to the 3' end by other nucleotides provided that the nucleotides introduced in positions 3 and 8 are forming a base pair (i.e., if the nucleotide position 3 is G, than that in position 8 is C; if the nucleotide in position 3 is C, than that in position 8 is G; etc.).

The 3' conserved regions of the wild-type influenza virus have the following sequences:

Influenza A: 5'-CCUGCUUUUGCU-3'

Influenza B: 5'-NN(C/U)GCUUCUGCU-3'

Influenza C: 5'-CCUGCUUCUGCU-3'.

Moreover, the 13 nucleotide conserved influenza 5'-terminal sequence may be modified by replacement of one or two nucleotides occurring in said sequence as positions 3 and 8 by other nucleotides, again provided that the introduced nucleotides are forming a base pair. The 5' conserved regions of the wild-type influenza virus have the following sequences:

Influenza A: 5'-AGUAGAAACAAGG

Influenza B: 5'-AGUAG(A/U)AACA(A/G)NN

Influenza C: 5'-AGCAGUAGCAAG(G/A):

- 10 Preferred influenza viruses of the invention are those wherein in the 3' conserved region the replacements G3A and C8U have been performed, more preferred are those where also the replacement U5C has been performed (the above mutations are relative to the 3' end; such counting from the 3' end is also indicated by a line on top of the digit, e.g., G  $\bar{3}$ A).
- 15 Another preferred influenza virus mutant comprises the 3'-terminal nucleotide sequence G3C, U5C and C8G (relative to the 3' end) giving the following 3' terminal nucleotide sequence 5'-CCUCGUUCUCCU-3'. Among the influenza viruses defined hereinbefore those having a 3'-terminal nucleotide sequence of 5'-CCUGUUUCUACU-3' are most preferred. In case
- 20 of an influenza A virus the segment may further have the modifications U3A and A8U in its 5' terminal sequence, in case of influenza C it may have the modifications C3U and G8A in its 5' terminal sequence. The most preferred influenza viruses of the present invention comprise the following general structures:

25 Influenza A (mutant pHL 1104):

5'-AGUAGAAACAAGGNNNU<sub>5,6</sub>..(880-2300 ntds)..N'N'N'CCUC $\overline{\text{U}}$ UU $\overline{\text{C}}$ U $\overline{\text{A}}$ CU-3'

Influenza A (mutant pHL 1920):

5'-AGAAGAAU $\overline{\text{C}}$ AAGGNNNU<sub>5,6</sub>..(880-2300 ntds)..N'N'N'CCUC $\overline{\text{U}}$ UU $\overline{\text{C}}$ U $\overline{\text{A}}$ CU-3'

Influenza A (mutant pHL 1948):

30 5'-AGUAGAAACAAGGNNNU<sub>5,6</sub>..(880-2300 ntds)..N'N'N'CCUC $\overline{\text{G}}$ UU $\overline{\text{C}}$ U $\overline{\text{C}}$ CU-3'

Influenza B:

5'-AGUAG(A/U)AACA(A/G)NNNNNU<sub>5-6</sub>..(880-2300 ntds)..N'N'N'N'(C/U)GUUUCUACU-3'

Influenza C:

5'-AGUAGUAACAAG(G/A)GU<sub>5-6</sub>..(880-2300 ntds)..CCCCUGUUUCUACU-3'

5

In the above structures the variables are defined as follows:

- (1) Underlined and enlarged letters show the required mutations relative to the wild-type sequence for preparing a promoter mutant with enhanced properties;
- 10 (2) enlarged A in the 5'-part of the sequence: additional A (position 10), angle-forming;
- (3) (A/G) at one position: different isolates or single segments with different sequence at this respective positions which are analytically interchangeable;
- 15 (4) N and N': undefined, but base paired positions relative to each other in complementarity between the 5' and 3' termini, different among the 8 segments, but constant for each segment throughout all viral isolates;
- (5) (880-2300 ntds): the lengths of the virus segments, in case of segments with foreign genes increased up to 4,000 nucleotides.

20

The pharmaceutical composition according to embodiment (7) above and the medicament of embodiment (8) above contains the recombinant influenza virus in a pharmaceutically effective amount. Besides said recombinant influenza virus, the pharmaceutical composition and the  
 25 medicament may contain further pharmaceutically acceptable carrier substances well-known to a person skilled in the art, such as binders, desintegrants, diluents, buffers, preservatives, etc. The pharmaceutical composition and medicaments are solid or liquid preparations and are suitable to be administered orally, intravenously or subcutaneously.

30

The medicament according to embodiment (8) above is preferably suitable as a medicament against influenza and/or against other infections. The

recombinant influenza virus may be present in form of inactivated preparations or may be present in form of live recombinant viruses, preferably as attenuated viruses.

- 5 Live recombinant viral vaccines, live but attenuated recombinant viral vaccines or inactivated recombinant viral vaccine can be formulated. Inactivated vaccines are "dead" in the sense that their infectivity has been destroyed. Ideally, the infectivity is destroyed without affecting its immunogenicity. To prepare inactivated vaccines, the recombinant virus  
10 may be grown in cell cultures or in embryonated chicken eggs, purified, and inactivated by formaldehyde or  $\beta$ -propiolactone. The resulting vaccine is usually administered intramuscularly.

- Inactivated viruses may be formulated with a suitable adjuvant to  
15 enhance the immunological response. Such adjuvants may include, but are not limited to mineral gels, e.g., aluminum hydroxide, surface-active substances such as pluronic polyols, lysolecithin, peptides, oil emulsions, and potential useful human adjuvants such as BCG.

- 20 Many methods may be used to introduce the vaccine formulations above, for example the oral, intradermal, intramuscular, intraperitoneal, subcutaneous, or intranasal routes. Where a live recombinant virus vaccine is used, it may be preferable to introduce the formulation via the natural route of infection for influenza virus.

- 25 The medicament according to embodiment (8) above is preferably suitable for prophylactic or therapeutic vaccination, or both, against influenza and other infections. For example, recombinant viruses can be made for use in vaccines against HIV, hepatitis B virus, hepatitis C virus, herpes viruses,  
30 papilloma viruses, to name but a few. In one embodiment the recombinant virus contains the genes for surface proteins of the viruses, in another the genes for non-structural or regulatory genes. The



recombinant viruses may be present in form of inactivated preparations or may be present in form of live recombinant viruses, or in live, but attenuated viruses. In an attenuated virus the recombinant virus would go through a single or very few propagation cycle(s) and induce a sufficient  
5 level of immune response, but would not cause disease. Such viruses lack one of the essential influenza genes or contain mutations to introduce temperature sensitivity.

The agents of embodiments (9)-(11) of the invention are applicable in ex  
10 *vivo* and *in vivo* application schemes. The RNA molecule to be expressed by means of the agent of the embodiment (11) is of an antisense sequence or double strand sequence (in ambisense bidirectional transcription) relative to a target cellular mRNA molecule. In embodiment (11) the agent is preferably suitable for sequence-specific gene silencing,  
15 preferably by antisense RNA or RNA interference mechanisms.

The method for the production of proteins or glycoproteins is preferably performed in cell culture cells or in fertilized chicken cells in accordance with standard techniques within the general knowledge of a person skilled  
20 in the art. The proteins or glycoproteins to be expressed are those incorporated into the ambisense construct as defined hereinbefore.

The methods according to embodiments (13) to (15), (17) and (18) of the invention include the administration of an effective amount to the mammal  
25 or the administration of a sufficient infective dose of the recombinant virus to the cell system that is used for ex vivo therapy or for in vitro investigations, whereby the amount and dose will be determined by a person skilled in the respective arts or knowledgeable of the desired treatments.

30

The agent of embodiment (16) of the invention is preferably utilized to infect, transfect or transduce patient-derived immune cells. The agent is

suitable for treatment of cancer or chronic viral infections. For this purpose, patient derived immune cells, preferably dendritic cells, are *ex vivo* infected with recombinant influenza viruses expressing, e.g., tumor antigens or viral antigens. The transduced cells are then reintroduced into  
5 the patient.

The preferred method for immunotherapy of embodiment (17) of the invention is an autologous immunotherapy, wherein the cells which are *ex vivo* infected are patient-derived and the transduced cells are reintroduced  
10 into the patient. The diseases to be treated by this method include cancer and chronic viral infections. For details regarding such treatment see discussion of embodiment (16) above.

The method for inducing antibodies according to embodiment (18) of the invention is suitable for inducing antibodies to foreign proteins including  
15 glycoproteins, following the administration of protein or glycoprotein antigens as part of a recombinant influenza virus in an authentic conformation, whereby the virus is purified by gentle procedures based on hemagglutination, and the gene is expressed at high rates in the infected  
20 cells.

As influenza viruses have a wide host range, recombinant influenza viruses can be used to obtain strong immune responses in, and isolate antibodies from, a wide range of animals, including, but not limited to,  
25 fowl, pigs, goats, horses, and mice. Further, influenza viruses adapted to the mouse can be used for the infection of mice, by several routes including the intranasal route. This results in infection of the pharyngeal mucosal cells and results in an additional type of B cell response (e.g., as recognized in the ratio of IgG to IgA). Mice are of particular utility in the  
30 induction of immune responses in transgenic mice that have been engineered to express human antibodies. As gentle procedures based on hemagglutination are used to purify influenza viruses, antibodies to

antigens in native conformation can be isolated from the infected mammals.

Further preferred embodiments of the invention are set forth herein  
5 below.

A. Construction of influenza helper virus strains carrying ribozyme  
target sequences in flanking positions within either of the vRNA  
segments

10

A.1: Influenza RNA polymerase will initiate transcription and replication from promoter structures located at internal positions in an RNA molecule, not only from the natural position at both ends of a vRNA molecule:

This is true in particular for promoter-up variants in RNA-internal location  
15 due to their enhanced binding affinity for viral polymerase. Not only 3' end extensions are tolerated in RNA-internal promoter recognition (Fig. 1), but also 5' extensions as well as extensions at both ends of the RNA template molecule, containing noncomplementary as well as complementary sequence, i.e. potentially present as a double-stranded extension. Finally,  
20 also an extension by way of duplication of the promoter sequence (active or inactivated) leads to mRNA transcription and CAT expression, initiated from the active pair of 5' and 3' promoter halves, irrespective if in external or in internal or even in an oblique localization (active 5' promoter sequence in external, active 3' promoter sequence in internal position, or  
25 vice versa). RACE-determination of the resulting 5' and 3' ends of viral mRNA and cRNA, i.e. the products of transcription and replication reactions for several of the extended template vRNA constructs proves an exact recognition and sequence-specific initiation at a position equivalent to regular 3' position 1: all of the various template extensions are lost in  
30 every product RNA molecule, most likely after only one round of replication.

A.2: Bicistronic (tandem) vRNA molecules carrying an additional 3' specific promoter sequence in a central position between its two genes can be used for an indirect selection method for recombinant influenza viruses:

The method described is applicable for any foreign gene (e.g. CAT) without a selection potential of its own, if inserted into the distal mRNA position (proximal vRNA position, in anti-sense orientation) behind a carrier gene (e.g. GFP) in the proximal mRNA position, able to serve as a transient selection marker. The carrier gene which is used for selection will get lost spontaneously during further propagation. These constructs are equivalent to a 3' extension of the template vRNA by a full-size gene of 750 nucleotides up to a second 3' promoter sequence, in terminal location. While in the set of experiments shown in Fig. 2 the external 3' promoter sequence is maintained throughout as the same promoter-up variant (1104), the internal 3' promoter sequence has been varied to include a full-level promoter-up variant (pHL2270, containing promoter mutant 1104), a medium-level promoter variant (pHL2350, containing promoter mutant 1948), a wildtype promoter construct (pHL2629), and a construct carrying an unrelated central sequence in an otherwise identical design (pHL2300).

Due to the presence of two 3' promoter sequences in conjunction with a single 5' promoter sequence an alternating interaction between them will constitute one or the other active promoter structure (see Fig. 3). While the external location with an adjacent RNA 3' end may have a structural advantage, this appears to be compensated by the shorter distance in an interaction between the 5' sequence and the central 3' sequence in constituting the internal promoter, such that the competition between the two primarily reflects the various internal 3' promoter allele sequences used, compare Fig. 2B and activity ratios indicated above and below the lanes. Translation of the mRNA-distal gene (CAT) is only observed following an internal initiation at the bicistronic vRNA template, resulting in

a spontaneous deletion of the mRNA-proximal (vRNA-distal) gene, GFP, compare right half of Fig. 3. In complementary analyses GFP fluorescence is observed initially for all of the bicistronic constructs, but gets lost on a faster rate from pHL2270 transfected and influenza infected cells (not shown), and will stay unchanged in pHL2300-treated cells. The indirect selection system based on bicistronic (tandem) molecules as designed here and demonstrated for reporter genes GFP and CAT can be used for any other gene without distinct phenotype upon insertion behind an unrelated carrier gene with properties useful in selection. - In employing that technique an initial phase of (repeated) positive selection for infected cells expressing that proximal trait (e.g. by FACS or by magneto-beads) will be followed by a second phase with negative selection, i.e. against that fraction of infected cells still exposing the same property.

15 A.3: Isolation of an influenza strain designed to carry 2x2 flanking ribozyme target sequences at the 5' and 3' end of vRNA segment 4 coding for hemagglutinin:

The above scheme for an indirect selection of any foreign recombinant gene behind a proximal carrier gene is further modified by deleting the carrier gene altogether. Instead, both 3' terminal promoter sequences (mutant and wildtype) follow each other at a short distance, separated only by a specific, repetitive ribozyme target sequence, - different from other target sequences to be described further below. The cDNA insert following after the second 3' promoter sequence consists mainly of a regular hemagglutinin (H7) coding sequence, however both the 5' and 3' vRNA terminal regions of the insert carry that other ribozyme target sequence (different from the first target sequence mentioned above) inserted in either location in tandem duplication (pHL2969, see Fig. 14).

Due to a superior replication supported by the promoter-up variant located in 3' external position the recombinant HA segment attached to that promoter sequence will become enriched during the first steps of viral propagation, while the originally dominating HA segment of the helper

virus which is under control of a wildtype promoter sequence is consecutively reduced and finally is no longer detectable among viral progeny. This result is documented by RT-PCR analysis of consecutive viral populations as obtained in that stepwise propagation procedure, see Fig.

5 4.

In the next step the viral lysate is twice passaged via infection of cell culture cells (293T) that before have been DNA-transfected by plasmid pAM403 (Fig. 15). This construct has been specifically designed to express a hammerhead ribozyme with flanking sequences complementary to the repetitive GUC-containing target sequence, as present twice in between the external and internal 3' promoter signals in the recombinant HA vRNA segment, see Fig. 5. In this way the extra promoter sequence is cut off from the finally resulting recombinant HA vRNA. Its promoter-up activity was useful in achieving an initial increase in the concentration of recombinant HA vRNA over wildtype HA vRNA, and in finally excluding the latter from further propagation. However, for the same reason that high activity of the promoter variant will cause instability in the resulting viral progeny, and an effective 'substitution' at this time through ribozyme cleavage by the internally located promoter signal, wild-type or slightly improved, will restore stability to the progeny viruses, with all of their eight vRNA segments now brought back in balance to each other. Due to the ribozyme cleavage site at 26 nucleotides 3' of the wild-type promoter sequence (see Fig. 5), in the initial stage that promoter signal is situated in a vRNA-internal location, extended by a 3' terminal sequence of 26 nucleotides. According to the data presented in Fig. 1 this should cause a transient slight reduction in activity, resulting however in one step in regular viral mRNAs and cRNAs, with any initially remaining extra sequence being lost from the finally resulting recombinant HA vRNA.

Progeny viruses still carrying an external promoter-up sequence (before ribozyme treatment or due to incomplete reaction) will not cause any plaque, due to over-replication of one vRNA segment relative to all others which results in a high load of defective particles. However, progeny

viruses which have lost that external promoter element due to ribozyme cleavage will yield regular plaques due to a balanced mode of replication for all eight wild-type or recombinant vRNA segments. Hence plaque purification is used for isolating a pure influenza viral strain carrying 2x2 ribozyme targets in its recombinant HA vRNA segment, with its termini reduced to the wild-type promoter sequence. The nature of the viral strain isolated has been confirmed in this regard by RT-PCR analysis, see Fig. 4. The above isolation procedure resulting in influenza viral strains carrying 2x2 flanking ribozyme target sequences has been performed twice for the HA coding segment (segment 4) to obtain two different isolates with regard to the orientation of the ribozyme target sequences. In one of the isolates (vHM41, see SEQ. ID NO: 3) the tandem target sites have been inserted into the HA vRNA non-translated sequence both in 5' and 3' location, while according to the second design that 5' tandem target sequence has been included in an inverted orientation, such that it is now present in the cRNA 3' sequence instead (vHM42).

In another experiment the same procedure was used to isolate an influenza strain carrying 2x2 tandem target sites within the 5' and 3' flanking positions of segment 8 vRNA, i.e. coding for genes NS1 and NS2 (vHM81; see SEQ.ID NO:4). And in principle the same could be done for any other influenza segment, in particular since only the reading frame cDNA sequence has been exchanged from HA to NS, with all of the flanking elements directly responsible for that procedure remaining in place, unchanged.

25

A.4: Ribozyme cleavage and vRNA segment exchange using ribozyme-sensitive influenza strains as helper viruses:

In an initial model experiment a range of ribozyme type and target site locations was probed in designing a series of CAT reporter gene vRNA constructs (analysed in the presence of a surplus of wildtype helper virus) in 293T cells. While all of the ribozyme constructs adhered to the hammerhead model, with 10 to 12 nucleotides of complementary

sequence flanking on either side of the GUC target site, these ribozyme constructs varied from monomer to dimer to trimer repetitions. Ribozyme containing mRNAs were synthesized *in vivo* via the basic vector plasmid pSV2-*neo*, i.e. using the efficient p<sub>SV40</sub> RNA polymerase II promoter element for expression, and the SV40 origin signal for plasmid amplification, in a cell line (293T or cos-1) with an incorporated SV40 T antigen gene. In addition the pSV2-*neo* mRNA includes the small, 63 nucleotide intron sequence of the SV40 early mRNA which is supposed to be spliced very slowly, thereby extending the pre-mRNA half-life in the nucleus. Each of the pSV2-*neo*-ribozyme plasmid constructs was transfected into 293T cells. Thereafter, recombinant viruses containing dimer target sites either near one end of the molecule only, or near both ends have been used for infection of the transfected cells. Relative activities of ribozyme constructs versus vRNA target sites have been measured via inactivation of CAT acetyl transfer rates in the cell lysates obtained at 8 h post infection (Fig. 6). The highest activities were observed for dimer ribozymes acting on vRNA molecules carrying 2x2 target sequences on both ends of the molecule, either in vRNA 5' and 3' location, or in vRNA 3' and cRNA 3' location, i.e. with an inversion of the target site sequence at the vRNA 5' end.

Consequently, the two constructs carrying tandem ribozyme double targets within both of their non-translated vRNA flanking sequences have been used in the design of ribozyme-sensitive influenza virus strains as described above, with both variants isolated for segment 4 (HA), and one of them for segment 8 (NS). In complementary correspondence the hammerhead ribozyme plasmid used has also been constructed as a double-headed structure with flanking sequences as shown in Fig. 7 (pAM424; for its detailed structure, see Fig. 16).

The three target site-containing influenza strains isolated as described above have been analysed for their sensitivity against ribozyme cleavage by infection of 293T cells, which had been DNA-transfected 18 h earlier by



ribozyme-producing plasmid pAM424, at DNA-transfection rates between 60 and 70 % (as observed in parallel transfections using GFP-expressing plasmid pAM505). Inactivation rates in these one-step control experiments were between 90% and 99% for all three ribozyme-sensitive strains, in  
5 their extent mainly depending upon the actual DNA-transfection rates achieved in individual experiments.

In the next step both isolates of HA-coding ribozyme-sensitive viruses, vHM41 and vHM42, have been used in marker-rescue experiments. Here, 293T cells have been first DNA transfected by HA-variant cDNA construct  
10 pHL2507 (see Fig. 17), followed after 18 h by vHM41 or vHM42 virus infections at moi 1. The resulting viral supernatant containing e.g. a mixture of ribozyme-sensitive vHM41 carrier virus and pHL2507/vHM41 recombinant virus is propagated in an intermediate step on MDCK cells, which also results in an increase in the fraction of recombinant viruses.  
15 Thereafter the resulting virus-containing supernatant is passaged through 293T (or cos-1) cells, which in advance have been transiently transfected by ribozyme-producing pAM424. As may be concluded from the above experiment (Fig. 6) and shown in Fig. 8 vHM41- or vHM42-derived ribozyme-sensitive HA vRNA segments are expected to be inactivated by  
20 pAM424-produced ribozyme down to a remaining level of about 1% to 10% (mainly present within cells that are infected, but not DNA-transfected).

Instead, the substitute HA vRNA which originated from pHL2507 plasmid  
25 DNA (ribozyme-resistant) becomes exclusively incorporated into progeny virions. For further purification and viral propagation these have been passaged a second time through 293T cells, again in advance DNA-transfected by pAM424, and after another amplification step on MDCK cells the resulting viral preparations have been used for RT-PCR analysis.  
30 The resulting viral populations in these marker rescue experiments only contain HA-vRNA molecules derived from pHL2507, which in their PCR

analyses are of intermediate size relative to wildtype HA-vRNA, and vHM41- or vHM42-derived HA-vRNAs, respectively.

Consequently, a set of ribozyme-sensitive influenza strains with targets inserted individually into every vRNA molecule may be used for such one-  
5 step marker rescue experiments in general, i.e. for vRNA segment exchange reactions performed in a directional way for any of the eight influenza vRNA segments, without requirement for a selectable change in phenotype (genetic marker).

10 B. Expression of two gene products from ambisense bicistronic influenza vRNA

B.1: The influenza cRNA promoter is active in antisense viral mRNA transcription according to the cap-snatching mode of initiation:

15 While the vRNA template of influenza virus is known to be active in viral mRNA as well as cRNA synthesis, the cRNA template has been described so far only to produce vRNA molecules, as a second step in viral replication. The potential activity of the cRNA promoter in initiating also viral mRNA transcription has not been analysed or even suspected so far,  
20 since no antisense (vRNA) reading frame can be detected in any of the viral RNA segments. Also, no U<sub>5</sub>/U<sub>6</sub> template sequence element is present in any of the viral cRNAs in an adjacent position to its 5' promoter structure as is the case for all viral vRNAs. This element is known to serve as a template sequence for mRNA terminal poly-adenylation, in repetitive  
25 interaction. However, when both elements are provided through reconstruction of an artificial influenza cRNA segment: a reading frame in opposite orientation (CAT), and a U<sub>6</sub> template element in 5' adjacent location, CAT expression can indeed be observed, see pHL2583 (see Fig. 18) in Fig. 9. Similar to the vRNA promoter the cRNA promoter activity is  
30 improved by (the same) promoter-up mutations, which essentially consist of basepair exchanges according to the 'corkscrew' model. This model apparently also holds for the cRNA promoter structure as analysed in a

5

10

15

the two reporter genes GFP and CAT have been arranged in opposite

20

25

cRNA promoter in the other (pHL2957). The whole set of constructs allows for a direct comparison with corresponding reference constructs carrying a regular vRNA promoter (pHL1844) or cRNA promoter structure (pHL2583), i.e. carrying only the 5'-adjacent U<sub>6</sub> sequence element and no 3'-A<sub>6</sub> counterpart. The two groups of constructs also differ in insert size, since a single inserted gene roughly accounts for 750 nucleotides, the convergent set of two genes for 1500 nucleotides, with the distal half of both mRNAs in this case remaining untranslated, a situation unusual for influenza viral mRNAs.

As is demonstrated in Fig. 10B for CAT expression of the various ambisense constructs all of them are able to initiate transcription in both orientations, even if at different levels with regard to their vRNA and cRNA promoter-dependent expressions, and also with regard to the insert lengths and convergent arrangements of the GFP/CAT versus CAT-only constructs. Analysis of the GFP expression rates (not shown) yields complementary results, i.e. again vRNA promoter-controlled GFP expression is superior over cRNA promoter expression of GFP. Therefore, individual ambisense clones either show an asymmetric high expression of GFP and low expression of CAT (pHL2960) or vice versa (pHL2989), depending on their orientation of reading frames with regard to the external vRNA and cRNA promoter. Fig. 10C also demonstrates successful propagation of recombinant viruses containing ambisense RNA molecules, which proves survival through amplification, packaging into virions, and expression of both mRNAs in infected MDCK cells (including besides CAT also GFP expression).

B.3: Construction of a superior promoter-up mutation, pHL1920, to be used for improved rates of cRNA promoter expression in ambisense constructs:

An extended analysis of promoter variants, in particular of complementary double exchanges according to the 'corkscrew' model yielded among others variant pHL1920 (Fig. 20) with CAT activity rates considerably

above (125-130% of) the rates observed for standard promoter-up variant '1104' (as present in pHL1844). The '1920' promoter-up variant consists of altogether 5 nucleotide substitutions relative to the wildtype promoter sequence, both in the 5' promoter element (2), and the 3' promoter element (3). The structure of this variant and the whole set of complementary double exchanges is presented in Fig. 11, together with the respective CAT activity measurements, in vRNA promoter constructs. vRNA promoter-up variants also show similarly improved expression in (ambisense) cRNA constructs, even if at generally lower levels than in vRNA constructs. cRNA promoter-up expression is observed at levels similar or somewhat (2x-5x) above the *wild-type* vRNA promoter rate, while vRNA promoter-up constructs show CAT expression rates increased up to 20 or 25 times the wild-type vRNA promoter level. In either case expression rates also depend on the size of the insert, with promoter activity rates decreasing with increasing lengths of the influenza RNA molecules to be transcribed.

B.4: Influenza recombinant viruses containing a foreign gene (CAT) in covalent ambisense linkage with one of the viral genes (HA, NS1/NS2):

The principle solution in designing stable recombinant viruses based on the new properties observed for influenza transcription and replication signals consists in constructing viruses which contain a foreign gene in covalent linkage with one of the (indispensable) viral genes, in ambisense bicistronic organization. Preferably the viral gene is connected to the cRNA promoter, while vRNA promoter expression is used for expression of the foreign gene at rates considerably above the viral mRNA synthesis. The promoter-up variant chosen for constructing the ambisense RNA segment intends to bring its cRNA promoter expression (approximately) into balance with all other viral gene expression levels, which are controlled by wild-type vRNA promoters located at the termini of the seven ordinary influenza segments; the respective choice has to take into consideration the overall length of the ambisense segment.

Isolation of the ambisense recombinant virus employs an RNA polymerase I-transcribed ambisense cDNA construct, which will give rise *in vivo* to ambisense cRNA-type molecules, see Fig. 12. The plasmid DNA transfection mixture used in this step with 293T cells in addition may or may not contain four 'booster' plasmids which under pCMV-control produce the four early influenza proteins from non-viral mRNAs: NP, plus PB1, PB2, and PA, i.e. the three subunits of viral polymerase (Pleschka et al., A plasmid-based reverse genetics system for influenza A virus J. Virol. 70, 4188-4192 (1996)), which will increase in a pre-amplification step the copy number of that ambisense viral cRNA segment. At 18 h post transfection the 293T cells are infected by a ribozyme-sensitive influenza strain, e.g. vHM41, which will supply (again) early and also late viral RNAs. The resulting supernatant which contains a mixture of vHM41 carrier virus and vHM41-derived ambisense recombinant virus (nine vRNA segments) is then passaged directly or via an intermediate step of amplification on MDCK cells onto 293T cells that have in advance been DNA-transfected by ribozyme-producing pAM424. Here, the ribozyme-sensitive vRNA segment of vHM41 will be cleaved at its 2x2 target sites by pAM424 specific ribozymes. In recombinant viruses the vRNA gene lost in this way is re-supplemented through its presence within the ambisense segment. The virus-containing supernatant is passaged for amplification and further purification through ribozyme treatment a second time on 293T cells which again have been pretreated by pAM424 DNA transfection. Absence of ribozyme-sensitive vRNA, and presence only of ambisense RNA in RT-PCR analysis at this stage allows for further amplification on MDCK cells and a final virus stock preparation on embryonated chicken eggs. CAT assays can be used to analyse for the presence and monitor the activity of this model foreign gene through the various steps of isolation and propagation as well as document technical improvements that might be worked out for one or more of the processive stages.

C. Examples for application of helper-free, stable recombinant influenza viruses

C.1: Incorporation of reporter gene GFP in NS/GFP or HA/GFP ambisense segments:

Recombinant viruses of this type will allow to follow-up on influenza infection instantly and continuously in individual infected cells, which may also be counted or documented by fluorescence photography or FACS sorting. With improved temperature resistance (Siemering et al.,  
10 Mutations that suppress the thermosensitivity of green fluorescent protein. Curr. Biol. 6, 1653-1663 (1993)) GFP expression becomes visible at 2 h after infection and shows bright fluorescence after 4 h p.i., it will be possible to follow-up on the spread of viral infection by GFP fluorescence. Stable fluorescence in abortively infected cells e. g. observed in *ex vivo*  
15 treatment of dendritic cells similarly supports a follow-up on their reincorporation into animals; other genes may be incorporated by ambisense vRNA into dendritic cells in the same way.

C.2: Construction of glycoprotein CSFV-E2 carrying influenza, helper-free:

The glycoprotein E2 of CSF virus has been incorporated previously into influenza both as an HA-anchor fusion protein within the viral envelope, and as an additional, unstable ninth vRNA segment into its genome (Zhou et al.; Membrane-anchored incorporation of a foreign protein in  
25 recombinant influenza virions. Virology, 246, 83-94 (1998)). Stabilization is now achieved through an ambisense connection with either of the regular viral RNA segments (NS or HA) which also allowed to reach a level of 100% recombinant viruses instead of an hitherto only 20% (Fig. 13), since all carrier viruses are destroyed through ribozyme action, see Figs. 8  
30 and 12. The helper virus containing preparation has already been used successfully as a vaccine against CSFV infection (antibody titers of 1:40000); the increase achieved in recombinant viruses allows a further

improvement in that regard. Also (cost-effective) propagation in fertilized chicken eggs has become possible due to its stable incorporation of the foreign gene as a covalent ambisense construct.

5 C.3: Construction of hepatitis C glycoprotein-carrying recombinant influenza viruses as a candidate vaccine:

Hepatitis C virus is a close relative of CSF virus (hog cholera virus), and in particular its set of two glycoproteins, small-size E1 and larger-size E2, is closely related in structural detail and presumably also in function to the  
10 corresponding CSFV proteins. An incorporation of HCV-E2/HA fusion proteins into influenza viral envelopes has been achieved in analogy to the CSFV-E2/HA incorporation. In addition, incorporation of an anchor-fusion glycoprotein HCV-E1/HA or both together (in NS *and* HA ambisense junctions) allows further variations in constructing an influenza-based  
15 vaccine for hepatitis C. In analogy to CSFV-E2, neutralizing antibodies are expected to be directed against particular epitopes of HCV-E2, presented in essentially native conformation at the influenza viral envelope.

20 C.4: Stable incorporation of selected influenza T-cell epitopes in ambisense constructions:

Influenza infection is known to result in both, antibody production against that specific viral strain or indeed its epitopes that are located mainly at the surface of HA, and in an increase of specifically primed cytotoxic T-lymphocytes, stimulated by T-cell epitopes primarily located within the  
25 essentially invariable core structure of the NP protein. While the humoral response will result in life-long immunity against *that particular* strain of influenza or its epitope structures, the T-cell response will be lost or severely reduced some time afterwards, such that its specificity against influenza in general will fall below protective levels. One way in trying to  
30 increase that level of cellular immunity is to enhance the response or recruitment of influenza-specific CTL cells by increasing the level of T-cell epitopes in the infected cell and hence its presentation on the surface by



MHC-I receptors. This is achieved by combining in an ambisense construct the HA gene and a series of repeated T-cell epitope sequences as present in the influenza NP gene, in a model design specific for the BALB/C mouse MHC-I allele. Here, the promoter-up expression rate is realized (in vRNA promoter-controlled initiation) for expression of the repetitive epitope polypeptide chain. Alternatively or in addition a controlled secretion of an interleukin can be achieved from recombinant influenza-infected cells, upon ambisense incorporation of the respective gene preferably into the NS segment. The interleukin to be chosen for this purpose (IL-12 or other) is selected to enhance the longevity of influenza-specific CTL cells or its conversion into corresponding memory cells. In this way an ambisense vaccine strain against influenza itself is achieved with expected protective capacity against influenza in general.

15 C.5: Exchange of influenza glycoproteins against foreign viral glycoproteins (VSV-G):

The 'marker rescue' experiment described above (section A.4.), i.e. an exchange of one HA gene (ribozyme-sensitive) for another (ribozyme-resistant) can also be used for an exchange of HA for an entirely different glycoprotein, such as the vesicular stomatitis virus G protein, as long as it is attached to the HA anchor segment. Effective incorporation depends always on that C-terminal tail sequence and its interaction with underlying matrix protein M1, and therefore, all constructions consist of fusion proteins in direct analogy to CSFV-E2. VSV-G with or without a foreign anchor sequence has been shown in several other viruses to be able to substitute for the original glycoprotein and to result in infectious viruses with VSV-G specific host-ranges (e.g. in retroviruses, rabies virus, measles virus). G protein in VSV itself as well as on the surface of foreign viruses is the only glycoprotein required for all of the consecutive steps in infection.

30 Insertion of VSV-G instead of HA in recombinant influenza viruses leaves the second glycoprotein, neuraminidase, without any function, which then will get lost spontaneously from the recombinant viruses. This will further

increase the capacity for an addition of foreign genes, beyond the gain resulting from an exchange of the larger HA for the smaller VSV-G, which might be used for an addition of ambisense constructs.

- 5 The invention is further illustrated in the accompanying figures.

### Detailed Description of the Figures

#### Fig.1: 3' nucleotide extensions of influenza vRNA template molecules:

- 10 (A) Murine B82 cells have been transfected by plasmid cDNA constructs designed to be transcribed into influenza vRNA molecules by RNA polymerase I *in vivo*, followed after 20 h by standard FPV<sub>Bratislava</sub> helper virus infection, at an moi of 1 to 3. In addition to reference plasmid pHL2024 (no extension), related cDNA constructs carrying extensions of 1  
15 to 50 bp, and hence extended by 1 to 50 nucleotides at the resulting vRNA 3' ends were used in parallel transfections; template extensions are marked at the top of the figure. Cell lysates prepared at 8 h post helper virus infections were used for CAT reactions using in one round 50 µl of cell lysate each, and in further analyses 5µl and 0.5 µl of lysate (not  
20 shown). Relative yields were determined in comparison to reference plasmid pHL2024, as indicated below the figure, with calculations restricted to those CAT assays showing less than 40% of substrate consumption, in three or more independent experiments.

- (B) Viral passage of B82 supernatants containing recombinant influenza  
25 virus onto MDCK cells, at an moi of 2 to 4, in average. Again at 8 h post infection cell lysates have been prepared and used for CAT assays. Relative yields as indicated below the figure have been determined in comparison to pHL2024 the same way as in (A), using 0.5 µl of cell lysate in each case. (The 50 µl CAT assays as shown here and also in the  
30 following figures intend to give an immediate impression of relative activities at always the same level, while the actual measurement data as

indicated below the lanes are obtained at various appropriate enzyme concentrations relative to reference pHL2024.)

Fig. 2: Propagation of recombinant influenza viruses with tandem bicistronic vRNA:

- (A) General design of expression plasmids for transient bicistronic vRNAs coding for GFP in the mRNA-proximal, and for CAT in the mRNA-distal position. Among the functional elements indicated are the human RNA polymerase I promoter ( $p_{IH}$ ) and murine rDNA terminator ( $t_I$ ) sequences, both hatched, and the 5' and 3' vRNA promoter cDNA sequences, open and closed boxes, respectively. For the vRNA-internal 3' promoter signal three variant sequences have been inserted as indicated below (positions 1 to 15 refer to 3'-terminal nucleotides in the resulting monocistronic vRNAs).
- (B) CAT assays as determined relative to pHL1844 (monocistronic CAT construct) after DNA transfection of 293T cells plus helper virus infection followed by one round of progeny viral propagation on MDCK cells are indicated *below* the lanes. Relative activities of the internal promoter sequences as indicated *above* the figure refer to measurements in a monocistronic *external* location of the same promoter variants (Flick *et al.*, Promoter elements in the influenza vRNA terminal structure, RNA 2, 1046-1057 (1996)). Control clone pHL2300 contains an unrelated, non-functional sequence in the central location in an otherwise identical plasmid construct.

Fig. 3: Tandem bicistronic vRNA sup-orting an alternative mode of transcription and replication initiation:

- An additional internal 3' promoter sequence has been inserted in between both cistrons, in a vRNA-central position. Left half: bicistronic replication and transcription leading to (proximal) GFP expression. Right half: internal initiation resulting in monocistronic replication and transcription leading to

(distal) CAT expression, and causing deletion of the GFP sequence from progeny molecules.

5 Fig. 4: Outgrowth of promoter-up recombinant vRNA versus wildtype vRNA segments in stepwise propagation of influenza virus:

RNA polymerase I transcription of transfected pHL2969 DNA results in influenza vRNA carrying (an external) promoter-up mutant '1104', and containing 2x2 ribozyme targets in flanking positions relative to its HA coding sequence. Another HA vRNA segment in wild-type configuration and originating from infecting FPV helper virus is also present in the recombinant virus preparation, initially (lane 1; 293T lysate) in surplus amounts, but reduced and finally lost entirely in consecutive steps of propagation (lanes 2 to 4; MDCK cell lysates), and in isolated strains after pAM403 ribozyme treatment for removal of the external '1104' promoter sequence (lane 5). Determination throughout by RT-PCR analyses using a pair of primers extending across the 5' inserted target site sequence, with 435 bp representing the recombinant HA segment, and 306 bp the wild-type sequence without an inserted target site sequence.

20 Fig.5: pAM403 ribozyme cleavage of pHL2969 derived vRNA molecules at specific target sites inserted between an external and an internal 3' promoter sequence:

The external promoter-up ('1104') signal is used for vRNA amplification within recombinant viruses and reduction of helper virus HA vRNA (Fig. 4), while the 'switch' to an internal wild-type signal guarantees stable replication of recombinant viruses. pAM403 hammerhead ribozyme RNAs are indicated in complementary binding to their target site sequences (12 and 10 nucleotides flanking the GU'C cleavage point) by straight lines flanking a central secondary structure symbol. vRNA-internal 2x2 ribozyme targets are marked by xx (see Fig. 7).

30

Fig. 6: Comparative cleavage analysis of model CAT vRNAs with tandem target sites in various flanking positions, by target-specific ribozymes:

293T tissue culture cells have been transiently DNA-transfected either by a single-headed hammerhead ribozyme (**s**), or a double-headed (**d**), or triple-headed (**t**) ribozyme cDNA construct, all specifically designed to hybridize to a tandem dimer target site sequence inserted in flanking positions into the CAT vRNA. All ribozyme RNAs have been expressed from the same pSV2-*neo* plasmid vector, including a pSV2-*neo* control construct without an inserted ribozyme cDNA sequence (**c**). At 20 h after DNA transfection (which reached 65% yield as measured by pCMV-GFP transfection in parallel of the same cell culture) the 293T cells were infected by CAT recombinant viruses carrying tandem double target sequences either only in vRNA-3' position, or in both vRNA-3' and 5' positions, or in both vRNA-3' and cRNA-3' positions. Most effective among the s, d, or t-ribozymes were double-headed constructs, acting on 2x2 targets inserted in either of the two localizations described (lanes 6 and 10).

Fig. 7: Alignment of pAM424 double-headed ribozyme with one of their repetitive target sequences located within the 5' and 3' vRNA flanking regions:

The superior activity of ribozymes oriented against targets located in the 3' end of vRNA molecules over those present in the 5' end instead (not shown) is in agreement with the model for influenza vRNA transcription and replication (Lamb and Krug, Orthomyxoviridae: The viruses and their replication. In 'Virology' (B.N.Fields, D.M.Knipe, P.M.Howley, R.M.Chanock, J.L.Melnick, T.P.Monath, B.Roizman, and S.E.Straus, Eds.), 3<sup>rd</sup> ed., Vol. 1, pp. 1353-1395. Lippincott-Raven, Philadelphia (1996)), according to which influenza polymerase stays attached to the 5' end of the vRNA molecule throughout the entire or even several rounds of transcription, whereas the very 3' end repeatedly, in every initiation reaction serves as the template sequence, and consequently is no longer covered by polymerase.

Superiority of a double-headed over a single-headed ribozyme has been determined earlier in this laboratory (A.Menke, Anti-Influenza Ribozyme: vRNA-Spaltung und intrazelluläre Aktivität. Dissertation Universität Giessen (1997)), but the substantial increase of vRNA inactivation rates  
5 upon incorporation of tandem target sites at both ends of the vRNA molecule instead of only one has been observed here for the first time, within that overall design.

Fig. 8: pAM424 ribozyme cleavage of resistant FPV wild-type HA vRNA and  
10 ribozyme-sensitive PHL2969-derived HA-vRNA in 293T cells infected by  
vHM41 after isolation from PHL2969-recombinant viral preparations.  
Lane 1: FPV infection of 293T cells, untreated; lane 2: FPV infection of 293T cells DNA-transfected by pAM424; lane 3: vHM41 infection of 293T cells, untreated; lane 4: vHM41 infection of 293T cells DNA-transfected by  
15 pAM424. RT-PCR analyses of purified viral progeny as in Fig. 4.

Fig. 9: Functional analysis of the influenza cRNA promoter structure:

(A) Schematic cRNA promoter ('1104') secondary structure according to the 'corkscrew' model; nucleotides involved in single or double nucleotide  
20 exchange are marked by their position.

(B) CAT analyses of 293T cell lysates after DNA transfection and FPV helper virus infection of cRNA promoter variants, in comparison to standard vRNA promoter-up mutant '1104' (pHL1844). Nucleotide substitutions divergent from the basic '1104' structure as present in  
25 pHL2583 or pHL2721 (see above) are indicated above the lanes, positions  $\bar{3}$  or  $\bar{8}$  as marked by a bar refer to cRNA positions counted from the 3' end. Relative CAT activities are marked below the lanes.

Fig.10: Functional analysis of the vRNA and cRNA promoter in ambisense  
30 arrangement:

(A) Sequence organisation of the ambisense promoter cDNA construct carrying T<sub>6</sub>/A<sub>6</sub> elements adjacent to the terminal sequence, and secondary structure predictions for the resulting cRNA and vRNA promoter signal.

- 5 (B) CAT expression data obtained from the cell lysates of 293T cell after plasmid DNA transfection and FPV infection, and (C) from cell lysates of MDCK cells after one step of viral passage. Indicated above the lanes are promoter/gene conjunctions: v = vRNA promoter; c = cRNA promoter.

Fig.11: Basepair substitutions according to the vRNA 'corkscrew' structure:

- 10 (A) 'Corkscrew' conformation of the vRNA promoter drawn against a schematic indication of interacting tripartite viral polymerase. Paired positions exchanged in individual experiments are indicated by numbers, nucleotides  $\bar{3}$  or  $\bar{8}$  are counted from the 3' end. pHL2024 containing promoter-up mutation '1104' is used as the reference construct (=100%)  
15 in all of the CAT assays, while pHL2428 represents the wild-type promoter structure.

(B) CAT expression data obtained after one step of viral passage in MDCK undiluted, and 50 fold diluted.

- 20 Fig. 12: Flow-chart of the isolation procedure for an ambisense recombinant influenza virus.

Fig. 13: Immuno-electron microscopy of purified influenza FPV/CSFV-E2-HA virions:

- 25 Recombinant viruses exposing the foreign glycoprotein CSFV-E2 in their envelopes, which has been fused onto the HA anchor domain, are marked by anti-E2 monospecific antibody and by secondary gold-labelled (5nm) goat antibody. Recombinant viruses (16%) are present together with their FPV helper viruses.

30

Fig. 14: pHL2969; the exact sequence of the 4930 bps circular DNA is shown in SEQ. ID NO:1.

Fig. 15: pAM403; the exact sequence of the 5811 bps circular DNA is shown in SEQ. ID NO:2.

5 Fig. 16: pAM424; the exact sequence of the 5860 bps circular DNA is shown in SEQ. ID NO:5.

Fig. 17: pHL2507; the exact sequence of the 4610 bps circular DNA is shown in SEQ. ID NO:6.

10

Fig. 18: pHL2583; the exact sequence of the 3558 bps circular DNA is shown in SEQ. ID NO:7.

Fig. 19: pHL2989; the exact sequence of the 4343 bps circular DNA is  
15 shown in SEQ. ID NO:8.

Fig. 20: pHL1920; the exact sequence of the 3888 bps circular DNA is shown in SEQ. ID NO:9.

20 Hence, the present invention is based on two surprising findings, namely  
1. influenza virus promoters are active when present internally in a gene;  
2. the so-called cRNA, thought to be an intermediate in replication can be turned into a protein-encoding RNA by equipping it with a variant influenza virus promoter, described in the present invention.

25

These two observations were used to make ambisense constructs. This allows to package an additional, foreign gene into influenza virus particles. Such particles were made previously, by other methods, but proved to be unstable, and therefore useless. For use as a vaccine for example, a  
30 helper virus would have been needed as a stabilizer. Stabilization in the present invention is achieved by several means. These include the "balancing" of one of the two promoters in the ambisense biscistronic



genetic construct with seven other vRNA wildtype promoters, while the additional promoter is used for high-rate expression of the foreign gene at various levels.

- 5 Thus, the present invention provides a system for expression of foreign proteins in higher eukaryotic systems. One system in particular is interesting, namely embryonated chicken eggs, as it allows cost-effective production in an automatable way (as used by most flu vaccine producers). The reason that this process is now possible, is that the  
10 foreign protein is part of a stable, engineered influenza virus particle. The virus can be designed also to rapidly monitor process improvements.

- An excellent use is of course the use of the construct as a vaccine. The influenza virus particle is immunogenic and can now be equipped with  
15 foreign antigens, enabling for example the design and production of hepatitis C virus and HIV vaccines, but also of tumor vaccines. As the present invention shows, the foreign antigenic surface glycoprotein is "fused" to a C-terminal segment of influenza HA, and the antigen then is presented at the surface of influenza virus particles. In addition, these  
20 vaccines can now be made in the way standard flu vaccines are made, i.e., in embryonated chicken eggs.

## Claims

1. A recombinant influenza virus for high-yield expression of incorporated  
5 foreign gene(s), which is genetically stable in the absence of any helper  
virus and which comprises at least one viral RNA segment being an  
ambisense RNA molecule (ambisense RNA segment) and containing one of  
the standard viral genes in sense orientation and a foreign, recombinant  
gene in anti-sense orientation, or *vice versa*, in overall convergent  
10 arrangement.
2. The recombinant influenza virus of claim 1, wherein at least one of the  
regular viral RNA segments is replaced by an ambisense RNA segment  
which contains one of the standard viral genes in sense orientation and a  
15 foreign, recombinant gene in anti-sense orientation, or *vice versa*, in  
overall convergent arrangement.
3. The recombinant virus according to claims 1 and 2, wherein in the  
ambisense RNA molecule said foreign recombinant gene is covalently  
20 bound to one of the viral genes, while the original vRNA segment coding  
for the same gene is deleted from the recombinant virus by way of specific  
ribozyme cleavage.
4. The recombinant influenza virus according to claims 1 to 3, wherein  
25 one or more of the regular viral RNA segments, differing from said at least  
one ambisense RNA segment, comprises a vRNA encoding a foreign gene,  
preferably one or more of the regular viral RNA segments has (have) been  
exchanged for a vRNA encoding a foreign gene.
- 30 5. The recombinant influenza virus according to claim 4 in which one or  
both of the standard glycoproteins hemagglutinin and neuraminidase have  
been exchanged into foreign glycoprotein(s) or into fusion glycoproteins

consisting of an anchor segment derived from hemagglutinin and an ectodomain obtained from the foreign source, viral or cellular, or in which such recombinant glycoprotein has been inserted as a third molecular species in addition to the remaining standard components.

5

6. The recombinant influenza virus according to claims 1 to 5, in which the terminal viral RNA sequences of one or more of the regular segments and/or of the at least one ambisense RNA segment, which are active as the promoter signal, have been modified by nucleotide substitutions in up to five positions, resulting in improved transcription rates of both the vRNA promoter as well as the cRNA promoter as present in the complementary sequence.

7. The recombinant influenza virus of claim 6, wherein the 12 nucleotide conserved influenza 3' terminal sequence has been modified by replacement of one to three nucleotides occurring in said sequence at positions 3, 5 and 8 relative to the 3' end by other nucleotides, and/or wherein the 13 nucleotide conserved influenza 5' terminal sequence has been modified by replacement of one or two nucleotides occurring in said sequence at positions 3 and 8 by other nucleotides.

25

8. The recombinant influenza virus of claim 7, wherein the replacements in the 3' terminal nucleotide sequence comprises the modifications G3A and C8U.

9. The recombinant influenza virus of claim 8, wherein the replacements in the 3' terminal nucleotide sequence comprises the modifications G3A, USC and C8U, or G3C, USC and C8G.

10. The recombinant influenza virus of claim 9, which comprises a 3' terminal nucleotide sequence of 5'-CCUGUUUCUACU-3'.

11. The recombinant influenza virus of claims 7 to 10, wherein the 5' terminal nucleotide sequence comprises the modifications U3A and A8U resulting in a 5'-terminal sequence of 5'-AGAAGAAUCAAGG.
- 5 12. The recombinant influenza virus according to claims 1 to 11, which is a recombinant influenza A virus.
13. The recombinant influenza virus according to claims 1 to 12, in which the foreign gene(s) in ambisense covalent junction with viral gene(s) code  
10 for proteins and/or glycoproteins which are secreted from cells infected with the recombinant virus.
14. The recombinant virus according to claims 1 to 12, in which the foreign gene(s) in ambisense covalent junction with viral gene(s) code for proteins  
15 or artificial polypeptides designed to support an efficient presentation of inherent epitopes at the surface of infected cells, for stimulation of a B cell and/or T cell response.
15. A method for the production of recombinant influenza viruses as  
20 defined in claims 1 to 14 comprising
- (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, in antisense, sense or ambisense design,
  - (b) followed by infection with an influenza carrier strain constructed to include flanking ribozyme target sequences in at least one of its viral RNA  
25 segments, and
  - (c) thereafter selective vRNA inactivation through ribozyme cleavage.
16. A method of constructing influenza carrier strains carrying one or more ribozyme target sites (of type one) in vRNA flanking positions  
30 comprising
- (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, carrying two different 3' promoter sequences in tandem, which are separated by a

second type of ribozyme target sequence, and which carry the said internal ribozyme target sites of type one;

(b) followed by infection of an influenza wildtype strain;

(c) thereafter amplification through simple steps of viral propagation; and

- 5 (d) finally isolation through removal of their external 3' promoter sequence by ribozyme cleavage through infection of cells expressing ribozyme type 2, followed by plaque purification.

- 10 17. A ribozyme-sensitive influenza carrier strain obtainable by the method of claim 16.

18. A pharmaceutical composition comprising a recombinant influenza virus according to claims 1 to 14.

- 15 19. Use of a recombinant influenza virus according to claims 1 to 14 for preparing a medicament for vaccination purposes.

20. The use according to claim 19, wherein the medicament

- (a) is suitable against influenza and/or against other infections;  
20 (b) is present in form of inactivated preparations; and/or  
(c) is present in form of live recombinant viruses.

21. Use of a recombinant influenza virus according to claims 1 to 14 for preparing agents for somatic gene therapy.

25

22. Use of a recombinant influenza virus according to claims 1 to 14 for preparing agents, for transfer and expression of foreign genes into cells infected by such viruses.

- 30 23. Use of a recombinant influenza virus according to claims 1 to 14 for preparing agents for transfer and expression of RNA molecules into cells infected by such viruses.


24. The use of claim 23, wherein the RNA molecules to be expressed are antisense sequences or double-strand sequences relative to the target cell cellular mRNA molecules, and/or the agent is suitable for sequence-specific gene silencing, preferably by antisense RNA or RNA interference mechanisms.
25. The use according to claims 21 to 24, wherein the agents are applicable in *ex vivo* and *in vivo* application schemes.
26. A method for the production of proteins or glycoproteins which comprises utilizing a recombinant influenza virus according to claims 1 to 14 as expression vector.
27. The method of claim 26, wherein the production is performed in cell culture cells or in fertilized chicken eggs.
28. A method for preventing and/or treating influenza which comprises administering an effective amount of a recombinant influenza virus according to claims 1 to 14 to the mammal to be treated.
29. A method for somatic gene therapy, which method comprises subjecting the organism to be treated with a recombinant influenza virus according to claims 1 to 14.
30. A method for transfer and expression of foreign genes into cells, and for transfer and expression of RNA molecules into cells, which method comprises infecting the cells with a recombinant influenza virus according to claims 1 to 14.
31. Use of a recombinant influenza virus according to claims 1 to 14 for preparing agents for autologous immunotherapy.

32. A method for an immunotherapy which comprises *ex vivo* infection of immune cells with a recombinant influenza virus according to claims 1 to 14, and introduction of the transduced cells into the patient.



5

33. A method for the induction of antibodies which comprises utilizing a recombinant influenza virus according to claims 1 to 14 as an immunogen.

Fig. 1












FIG. 4



5/21

FIG. 5



SUBSTITUTE SHEET (RULE 26)

FIG. 6




FIG. 7




FIG. 8





FIG. 9



**SUBSTITUTE SHEET (RULE 26)**






FIG. 10






Fig. 10 (continued)




A

FIG. 11




| bp-variant<br>position | G - C            | A - U            | C - G            | U - A            |
|------------------------|------------------|------------------|------------------|------------------|
| 2 - 9                  | pHL 2024<br>100% | pHL 1921<br>41%  | pHL 2003<br>< 3% | pHL 2004<br>< 3% |
| 3 - 8                  | pHL 2002<br>36%  | pHL 1920<br>121% | pHL 1148<br>63%  | pHL 2024<br>100% |
| 1 - 9                  | pHL 1945<br>11%  | pHL 1946<br>30%  | pHL 2024<br>100% | pHL 1923<br>28%  |
| 3 - 8                  | pHL 2428<br>6%   | pHL 2024<br>100% | pHL 1948<br>33%  | pHL 1922<br>97%  |

B




C



13/21

FIG. 12




SUBSTITUTE SHEET (RULE 26)

FIG. 13



FIG. 14




16/21  
FIG. 15

FIG. 16






FIG. 17







FIG. 18







## SEQUENCE LISTING

&lt;110&gt; ARTEMIS PHARMACEUTICALS GmbH

5 <120> Stable Recombinant Influenza Viruses Free of Helper  
Viruses

&lt;130&gt; 000520wo/JH/ml

10 <140>  
<141>

&lt;160&gt; 25

15 &lt;170&gt; Patentin Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 4939

20 &lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: pHL2969

25

&lt;400&gt; 1

|    |             |            |             |             |             |             |      |
|----|-------------|------------|-------------|-------------|-------------|-------------|------|
|    | cgtacgaagc  | ttctagaggg | attggctgag  | acgaaaaaca  | tatgctagag  | ggattggctg  | 60   |
|    | agacgaaaaa  | catatgctag | agcggccgcc  | accgcggtgg  | agctccagct  | tttgtccct   | 120  |
|    | ttagttaggg  | tttaattgag | gcaggcctag  | ctaggtaaaag | aaaaatcccc  | ttgtttctac  | 180  |
| 30 | taataacccg  | gcggcccaaa | atgccgactc  | ggagcgaaag  | atatacctcc  | cccggggccg  | 240  |
|    | ggaggtcgcg  | tcaccgacca | cgccgcgggc  | ccaggcgacg  | cgcgacacgg  | acacctgtcc  | 300  |
|    | ccaaaaacgc  | caccatcgca | gccacacacg  | gagcgcccg   | ggccctctgg  | tcaacccag   | 360  |
|    | qacacacgcg  | ggagcagcgc | cgggccgggg  | acgcccctcc  | ggccgcccgt  | gccacacgca  | 420  |
|    | gggggcccgc  | ccgtgtctcc | agagcgggag  | ccggaagcat  | tttcggcccg  | ccccctctac  | 480  |
| 35 | qaccgggaca  | cacgagggac | cgaaggcccg  | ccaggcgcg   | cctctcgggc  | cgcacgcgcg  | 540  |
|    | ctcagggagt  | gctctccgac | tccgcacggg  | gactcgccag  | aaaggatcgt  | gacctgcatt  | 600  |
|    | aatgaatcag  | gggataacgc | aggaaaagaac | atctgaqcaa  | aaggccagca  | aaaggccagg  | 660  |
|    | aaccgtaaaa  | agccgcgcgt | gctggcgctt  | ttccataggc  | tccgcccccc  | tgacgagcat  | 720  |
|    | cacaaaaatc  | gacgctcaag | tcagaggtgg  | cgaaccccca  | caggactata  | aagataccag  | 780  |
| 40 | gcgtttcccc  | ctggaagctc | cctcgtgcgc  | tctctctctc  | cgacctgtcc  | gcttaccgga  | 840  |
|    | tacctgtccg  | cctttctccc | ttcgggaagc  | ggggcgcttt  | ctcatagctc  | acgctgtagg  | 900  |
|    | tatcttcagtt | cggtgtaggt | cgttcgctcc  | aaactgggct  | gtgtgcacga  | acccccgctt  | 960  |
|    | cagcccgacc  | gctgcgcctt | atccggtaac  | tatcgtcttg  | agtcacaacc  | ggtaagacac  | 1020 |
|    | gacttatcgc  | cactggcagc | agccactggt  | aacaggatta  | gcagagcgag  | gtatgtaggc  | 1080 |
| 45 | ggtgctacag  | agttcttgaa | gtggtggcct  | aactacggct  | acactagaag  | gacagtattt  | 1140 |
|    | ggtatctgcg  | ctctgctgaa | gccagttacc  | ttcggaaaaa  | gagttggtag  | ctcttgatcc  | 1200 |
|    | ggcaaaacaa  | ccaccgctgg | tagcggtggg  | ttttttgttt  | gcaagcagca  | gattacgcgc  | 1260 |
|    | agaaaaaaag  | gatctcaaga | agatcctttg  | atctttttcta | cgggggtctga | cgctcagtg   | 1320 |
|    | aacgaaaaact | cacgttaagg | gattttgggt  | atgagattat  | caaaaaggat  | cttcacctag  | 1380 |
| 50 | atcctttttaa | attaaaaatg | aagtttttaa  | tcaatctaaa  | gtatatatga  | gtaaacttgg  | 1440 |
|    | tctgacagtt  | accaatgctt | aatcagtgag  | gcacctatct  | cagcgatctg  | tctatttctg  | 1500 |
|    | tctatccatag | ttgcttgact | ccccgtcggt  | tagataacta  | cgatacggga  | gggcttacca  | 1560 |
|    | tctggcccca  | gtgctgcaat | gataccgcga  | gacccacgct  | caccggctcc  | agatttatca  | 1620 |
|    | gcaataaacc  | agccagccgg | aagggccgag  | cgcagaagtg  | gtcctgcaac  | tttatccgcc  | 1680 |
| 55 | tccatccagc  | ctattaattg | ttgccgggaa  | cctagagtaa  | gtagttcgcc  | agttaatagt  | 1740 |
|    | ttgcgcaacg  | ttgttgccat | tgctacaggc  | atcgtggtgt  | cacgctcgct  | gtttgggtatg | 1800 |
|    | gcttcattca  | gctccgggtc | ccaacgatca  | aggcgagtta  | catgatcccc  | catgttgctg  | 1860 |
|    | aaaaaaagcg  | ttagctcctt | cgtctctccg  | atcgttgctc  | gaagtaagtt  | ggccgcagtg  | 1920 |
|    | ctatcactca  | tggttatggc | agcactgcac  | aattctctta  | ctgtcatgcc  | atccgtaaga  | 1980 |
| 60 | tgcttttctg  | tgactgggtg | gtactcaacc  | aagtcattct  | gagaatagtg  | tatgcggcga  | 2040 |
|    | ctcaggttgc  | cttgcccgcc | gtcaacacgc  | gataataccg  | cgccacatag  | cagaacttta  | 2100 |

|    |  |             |             |             |             |             |      |
|----|--|-------------|-------------|-------------|-------------|-------------|------|
|    | aaagtgcctca                                      | tcattggaaa  | acgtttcttcg | ggggcgaatac | tctcaaggat  | cttaccgctg  | 2160 |
|    | ttgagatcca                                       | gttcgatgta  | accactcgt   | gcacccaact  | gatcttcagc  | atcttttact  | 2220 |
|    | ttcaccagcg                                       | tttctgggtg  | agcaaaaaca  | ggaaggcaaa  | atgccgcaaa  | aaagggaata  | 2280 |
|    | agggcgacac                                       | ggaaatgttg  | aatactcata  | ctcttctttt  | ttcaatatta  | ttgaagcatt  | 2340 |
| 5  | tatcagggtt                                       | attgtctcat  | gagcggatac  | atatttgaat  | gtatttagaa  | aaataaaca   | 2400 |
|    | aaagagttgt                                       | agaaaacgaa  | aaaggccatc  | cgtcaggatg  | gccttctgct  | taatttgatg  | 2460 |
|    | cctggcagtt                                       | tatggcgggc  | gtcctgcccg  | ccaccctccg  | ggcggttgct  | tcgcaacgtt  | 2520 |
|    | caaatccgct                                       | cccggcggat  | ttgtcctact  | caggagagcg  | ttcaccgaca  | aacaacagat  | 2580 |
|    | aaaacgaaag                                       | gcccagttct  | tcgactgagc  | cttctcgttt  | atttgatgcc  | tggcagttcc  | 2640 |
| 10 | ctactctcgc                                       | atggggagac  | cccacactac  | cctcggcgct  | acggcgctttc | acttctgagt  | 2700 |
|    | tcggcatggg                                       | gtcagggtgg  | accaccggcg  | tactgccgce  | aggcaaatcc  | tggtttatca  | 2760 |
|    | gaccgcttct                                       | gcgttctgat  | ttaatctgta  | tcaggctgaa  | aatcttctct  | catccgccaa  | 2820 |
|    | aacagaagct                                       | agcggccgat  | ccccaaaaaa  | aaaaaaaaaa  | aaaaaaaaaa  | gagtcagag   | 2880 |
|    | tgcccccggc                                       | gttccgcgce  | gggggggggg  | gggggggggg  | acactttcgg  | acatctggtc  | 2940 |
| 15 | gacctccagc                                       | atcgggggaa  | aaaaaaaaaa  | caaaagtctc  | cccggagtac  | tggtcgacct  | 3000 |
|    | ccgaagtggg                                       | gggggagtag  | aaacagggtg  | gataatcact  | cactgacgta  | cggtgagcaa  | 3060 |
|    | ctgactgaaa                                       | tgccctgagc  | aactgactga  | aatgcctgac  | gtctttagca  | aaagcaggg   | 3120 |
|    | agataatcac                                       | tcactgagtg  | acatccacat  | cgtaccagga  | tggtctgaga  | cgaaaaacat  | 3180 |
|    | attgtaccag                                       | ggattggctg  | agacgaaaaa  | catattgtag  | gtaccaaaat  | gaacactcaa  | 3240 |
| 20 | atcttggttt                                       | tcgcccctgc  | ggcagtcac   | cccacaaaat  | cagacaaaat  | ttgtcttggg  | 3300 |
|    | catcatgctg                                       | tatcaaatgg  | caccaaagta  | aacacactca  | ctgagagagg  | agtagaagtt  | 3360 |
|    | gtcaatgcaa                                       | cggaaacagt  | ggagcggaca  | aacatcccca  | aaatttgctc  | aaaagggaaa  | 3420 |
|    | agaaccactg                                       | atcttgccca  | atgcggactg  | ttagggaacca | ttaccggacc  | acctcaatgc  | 3480 |
|    | gaccaatttc                                       | tagaattttc  | agctgatcta  | ataatcgaga  | gacgagaagg  | aaatgatgtt  | 3540 |
| 25 | tggtaccggg                                       | ggaaagtgtg  | taatgaagag  | gcattgcgac  | aaatccctcag | aggatcaggt  | 3600 |
|    | gggattgaca                                       | aagaaacaat  | gggattcaca  | tatagtggaa  | taaggaccaa  | cggaacaact  | 3660 |
|    | agtgcattga                                       | gaagatcagg  | gtcttcattc  | tatgcagaaa  | tggaagtggc  | cctgtcaaat  | 3720 |
|    | acagacaatg                                       | cttctttccc  | acaaatgaca  | aaatcataca  | aaaacacagg  | gagagaatca  | 3780 |
|    | gctctgatag                                       | tcctggggaat | ccaccattca  | ggatcaacca  | ccgaacagac  | caaactatat  | 3840 |
| 30 | gggagtggaa                                       | ataaactgat  | aacagtcggg  | agttccaaat  | atcatcaatc  | tttctgtgccg | 3900 |
|    | agtcaccagg                                       | cacgaccgca  | gataaatggc  | cggtcgggac  | ggattgattt  | tcatttggtt  | 3960 |
|    | atcttggaat                                       | ccaatgatac  | agttactttt  | agtttcaatg  | gggctttcat  | agctccaaat  | 4020 |
|    | cctggccagct                                      | tcttjagggg  | aaagtccatg  | gggatccaga  | gcgatgtgca  | ggttgatgct  | 4080 |
|    | aatttggaag                                       | gggaatgcta  | ccacagtggg  | gggactataa  | caagcagatt  | gccttttcaa  | 4140 |
| 35 | aacataaata                                       | gcagagcagc  | tgccaaatgc  | ccaagatatg  | taaaacagga  | aagtttatta  | 4200 |
|    | trggcaactg                                       | ggatgaagaa  | cgttcccga   | ccttccaaaa  | aaaggaaaaa  | aaagggcctg  | 4260 |
|    | tttggtgcta                                       | tagcagggtt  | tattgaaaat  | ggttgggaag  | gtctgggtcga | cggttggtac  | 4320 |
|    | ggtttcaggc                                       | atcagaatgc  | acaaggagaa  | ggaactgcag  | cagactacaa  | aaagcaccaa  | 4380 |
|    | tcggcaattg                                       | atcagataac  | cggaaaagta  | aatagaactca | ttaaagaaaac | caaccagcaa  | 4440 |
| 40 | tttgagctaa                                       | tagataatga  | attcactgaa  | gtggaaaaagc | agattggcaa  | tttaattaac  | 4500 |
|    | tggaacaaa  | actccatcac  | agaagtatgg  | tcttacaatg  | ctgaacttct  | tggtggcaatg | 4560 |
|    | gaaaaccagc                                       | acactattga  | tttggtgat   | tcagaagtga  | acaagctgta  | tgagcgagtg  | 4620 |
|    | aggaaacaat                                       | taagggaata  | tgctgaagag  | gatggcactg  | gttgctttga  | aatttttcat  | 4680 |
|    | aaatgtgacg                                       | atgattgtat  | ggctagtata  | aggaacaata  | cttatgatca  | cagcaaatat  | 4740 |
| 45 | agagaagaag                                       | cgatgcataa  | tagaatacaa  | attgacccag  | tcaaattgag  | tagtggtctac | 4800 |
|    | aaagatgtga                                       | tactttggtt  | tagcttcggg  | gcacatgct   | ttttcttct   | tgccattgca  | 4860 |
|    | atgggccttg                                       | ttttcatatg  | tgtgaagaac  | ggaaacatgc  | ggtgcactat  | atgcatttaa  | 4920 |
|    | agcttgcatg                                       |             |             |             |             |             | 4930 |
| 50 | <210> 2  |             |             |             |             |             |      |
|    | <211> 5811                                       |             |             |             |             |             |      |
|    | <212> DNA  |             |             |             |             |             |      |
|    | <213> Artificial Sequence                        |             |             |             |             |             |      |
| 55 | <220>  |             |             |             |             |             |      |
|    | <223> Description of Artificial Sequence: pAM403 |             |             |             |             |             |      |
|    | <400> 2  |             |             |             |             |             |      |
| 60 | aattcttttg                                       | cccaatttaa  | atgaggactt  | aacctgtgga  | aatattttga  | tggtgggaagc | 60   |
|    | ttttactgtt                                       | aaaactgagg  | ttattggggg  | aactgctatg  | ttaaacttgc  | attcagggac  | 120  |

|    |             |             |             |             |            |             |      |
|----|-------------|-------------|-------------|-------------|------------|-------------|------|
|    | acaaaaaact  | catpaaaaatg | gtgctggaaa  | accatttcaa  | gggtcaaat  | ttcattttt   | 180  |
|    | tgctgttgg   | ggggaacctt  | tgagctgca   | gggtgtgtta  | gcaaactaca | ggaccaaata  | 240  |
|    | tcctgtctaa  | actgtaaccc  | caaaaaatgc  | tacagttgac  | agtcagcaga | tgaacactga  | 300  |
|    | ccacaaggct  | gttttggata  | aggataatgc  | ttatccagtg  | gagtgctggg | ttcctgatcc  | 360  |
| 5  | aagtaaaaa   | gaaaacacta  | gatatatttg  | aacctacaca  | ggtggggaaa | atgtgcctcc  | 420  |
|    | tgttttgcac  | attactaaca  | cagcaaccac  | agtgcctctt  | gatgagcagg | gtgttgggcc  | 480  |
|    | cttggtgcaa  | gctgacagct  | tgatgtttc   | tgctgttgac  | atttgtgggc | tgtttaccaa  | 540  |
|    | cacttctgga  | acacagcagt  | ggaagggaact | tcccagatat  | tttaaaatta | cccttagaaa  | 600  |
|    | gcggtctgtg  | aaaaacccct  | acccaatttc  | ctttttgtta  | agtgcctaa  | ttacaggag   | 660  |
| 10 | gacacagagg  | gtggatgggc  | agcctatgat  | tggaatgtcc  | tctcaagtag | aggagggttag | 720  |
|    | ggtttatgag  | gacacagagg  | agcttccctg  | ggatccagac  | atgataagat | acattgatga  | 780  |
|    | gtttgggaaa  | accacaacta  | gaatgcagtg  | aaaaaaatgc  | tttatttgtg | aaatttgtga  | 840  |
|    | tgctattgct  | ttatttgtaa  | ccattataag  | ctgcaataaa  | caagttaaca | acaacaattg  | 900  |
|    | cattcatattt | atgtttcagg  | ttcaggggga  | gggtgtgggag | gttttttaaa | gcaagtaaaa  | 960  |
| 15 | cctctacaaa  | tggtgtatgg  | ctgattatga  | tctctagtca  | aggcactata | catcaaatat  | 1020 |
|    | tccttattaa  | ccccctttaca | aattaaaaag  | ctaaagggtac | acaatttttg | agcatagtta  | 1080 |
|    | tttaatagcag | acactctatg  | cctgtgtgga  | gtaagaaaaa  | acagtatgtt | atgattataa  | 1140 |
|    | ctgttatgcc  | tacttataaa  | ggttacagaa  | tatttttcca  | taattttctt | gtatagcagt  | 1200 |
|    | gcagcttttt  | cttttgtgg   | gtaaatagca  | aagcaagcaa  | gagttctatt | actaaacaca  | 1260 |
| 20 | gcattgactca | aaaaacttag  | caattctgaa  | ggaaagtcct  | tggggtcttc | tacctttctc  | 1320 |
|    | ttcttttttg  | gaggagttaga | atgttgagag  | tcagcagtag  | cctcatcatc | actagatggc  | 1380 |
|    | attttctctg  | agcaaaaacag | gttttctcca  | ttaaaggcat  | tccaccactg | ctcccaattca | 1440 |
|    | tcagttccat  | aggttggaa   | ctaaaataca  | caaacaatta  | gaatcagtag | tttaacacat  | 1500 |
|    | tatacactta  | aaaattttat  | atttacctta  | gagctttaaa  | tctctgtagg | tagtttgcct  | 1560 |
| 25 | aattatgtca  | caccacagaa  | gtaagggtcc  | ttcacaaaga  | tccgggacca | aagcggccat  | 1620 |
|    | cgtgcctccc  | cactcctgca  | gttcgggggc  | atggatgcgc  | ggatagccgc | tgctggtttc  | 1680 |
|    | ctggatgccg  | acggatttgc  | actgcccgtg  | gaactccgcg  | aggtcgtcca | gcctcaggca  | 1740 |
|    | gcagctgaac  | caactcgcga  | ggggatcgag  | cccggggtgg  | gcgaagaact | ccagcatgag  | 1800 |
|    | atccccgcgc  | tgaggatca   | tccagccggc  | gtcccggaaa  | acgattccga | agcccaacct  | 1860 |
| 30 | ttcatagaag  | gcggcggtgg  | aatcgaaatc  | tcgtgatggc  | aggttgggcg | tcgctcggtc  | 1920 |
|    | ggtcatttctg | atgaattcga  | gctcgggtacc | cggggatcct  | ctagaggcat | ttcagtttctg | 1980 |
|    | tcctcacgga  | ctcatcagag  | ttgctcaatt  | cgaacccag   | agtcgccgtc | agaagaactc  | 2040 |
|    | gtcaagaagg  | cgatagaagg  | cgatgcgctg  | gcaatcggga  | gcggcgatc  | cgtaaaagc   | 2100 |
|    | gaggaagcgg  | tcagcccat   | cgccgccaa   | ctcttcagca  | atatcacggg | tagccaacgc  | 2160 |
| 35 | tatgtcctga  | tagcggtccg  | ccacacccag  | ccggccacag  | tcgatgaatc | cagaaaagcg  | 2220 |
|    | gocattttcc  | accatgatat  | tcggcaagca  | ggcatcgcca  | tggttcacga | cgagatcctc  | 2280 |
|    | gcgcctgggc  | atgcgcgcct  | tgagccttgc  | gaacagttcg  | gctggcgcg  | gcccctgatg  | 2340 |
|    | ctcttcgctc  | agatcatcct  | gatcgacaag  | accggcttcc  | atccgagtac | gtgctcgctc  | 2400 |
|    | gatgcgatgt  | ttcgcttgg   | ggtcgaaatg  | gcaggtagcc  | ggatcaagcg | tatgcagccg  | 2460 |
| 40 | ccgcatttga  | tcagccatga  | tcgatacttt  | ctcggcagga  | gcaaggtgag | atgacaggag  | 2520 |
|    | atcctgcccc  | ggcacttcgc  | ccaatagcag  | ccagtccctt  | cccgttccag | tgacaacgct  | 2580 |
|    | gagcagagct  | gcgcaaggaa  | cgcccgctcg  | ggccagccac  | gatagccgcg | ctgctcctgc  | 2640 |
|    | ctgcagttca  | ttcagggcac  | cggacaggtc  | ggtcttgaca  | aaaagaaccg | ggcgcccttg  | 2700 |
|    | cgctgacagc  | cggaacacgg  | cggcatcaga  | gcagccgatt  | gtctgttgtg | cccagtcata  | 2760 |
| 45 | gccgaatagc  | ctctccaccc  | aagcggccgg  | agaacctgcg  | tgcaatccat | cttgttcaat  | 2820 |
|    | catgcgaaac  | gatcctcatc  | ctgtctcttg  | atcagatctt  | gatcccttgc | gccatcagat  | 2880 |
|    | ccttggcggc  | aagaaagcca  | tcagtttctg  | tttgcaggcg  | ttcccaacct | taccagaggg  | 2940 |
|    | cgccccagct  | ggcaatttcg  | gttcgcttgc  | tgccataaaa  | accgcccagt | ctagctatcg  | 3000 |
|    | ccatgtaagc  | ccactgcaag  | ctacctgctt  | tctctttgcg  | cttgcgtttt | cccttgtcca  | 3060 |
| 50 | gatagcccag  | tagctgacat  | tcattccggg  | tcagcaccgt  | ttctgcggac | tggttttcta  | 3120 |
|    | cgtgttccgc  | ttccttttag  | agcccttgcg  | ccctgagtgc  | ttgcggcagc | gtgaagcttt  | 3180 |
|    | ttgcaaaaag  | ctaggccctcc | aaaaaagcct  | cctcactact  | tctggaatag | ctcagaggcc  | 3240 |
|    | gaggcgccct  | cggcctctgc  | ataaatataa  | aaaatttagt  | agccatgggg | cggagaattg  | 3300 |
|    | gcggaactgg  | gcggagttag  | gggcgggatg  | ggcgagttta  | ggggcgggac | tatggttctg  | 3360 |
| 55 | gactaattga  | gatgcattgt  | ttgcatactt  | ctgcctgctg  | gggagcctgg | ggactttcca  | 3420 |
|    | cacctggttg  | ctgactaatt  | gagatgcatg  | ctttgcatac  | ttctgcctgc | tggggagcct  | 3480 |
|    | ggggactttc  | cacacccctaa | ctgacacaca  | ttccacagct  | gcctcgcgcg | tttcggtgat  | 3540 |
|    | gacgggtgaaa | acctctgaca  | catgcagctc  | ccggagacgg  | tcacagcttg | tctgtaagcg  | 3600 |
|    | gatgccggga  | gcagacaagc  | ccgtcagggc  | gcgtcagcgg  | gtgttggcgg | gtgtcggggc  | 3660 |
| 60 | gcagccatga  | cccagtcacg  | tagcgatagc  | ggagtgtata  | ctggcttaac | tatgcggcat  | 3720 |
|    | cagagcagat  | tgtactgaga  | gtgcaccata  | tcgggtgtga  | aataccgcac | agatgcgtaa  | 3780 |

ggagaaaata ccgcatcagg cgctcttcgg ctctcctcgg cactgactcg ctgcgctcgg 3840  
 tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag 3900  
 aatcagggga taacgcagga aagaacatgt gagcaaaaag gccagggaacc 3960  
 5 gtaaaaagcg cgcgttgctg gcgtttttcc ataggctccg ccccttgac gagcatcaca 4020  
 aaaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt 4080  
 ttccctcctg aagctccctc gtgcgctcct ctgttcggac cctgccgctt accggatacc 4140  
 tgcctgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc tgtaggatc 4200  
 tcagttcggg taggtcgtt cgctccaagc tgggctgtgt gcacgaacc cccgttcagc 4260  
 ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caaccggta agacacgact 4320  
 10 tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggat gtaggcgtg 4380  
 ctacagagtt ctgaagtgg tggcctaact acggctacac tagaaggaca gtatttggt 4440  
 tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca 4500  
 aacaaaccac cgctggtagc ggtgggtttt ttgtttgcaa gcagcagatt acgcgcagaa 4560  
 aaaaaggatc tcaagaagat cctttgatct ttctacggg gtctgacgct cagtggagc 4620  
 15 aaaaactcacg ttaagggtt ttggtcatga gattatcaaa aaggatcttc acctagatcc 4680  
 ttttaaatca aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggctcg 4740  
 acagttacca atgttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcac 4800  
 ccatagttgc ctgactcccc gtctgttaga taactacgat acgggagggc ttaccatctg 4860  
 gcccagtgct tgcaatgata ccgcgagacc cagctcacc ggctccagat ttatcagcaa 4920  
 20 taaaccagcg agccggaagg gccgagcgca gaagtgttcc tgcaacttta tccgcctcca 4980  
 tccagttctat taattgttgc cgggaagcta gagtaagtag ttccgcagtt aatagtttgc 5040  
 gcaacgttgc tgccattgct gcaggcatcg tgggtgtcac ctgcctcgtt ggtatggctt 5100  
 cattcagctc cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa 5160  
 aagcgggttag ctcttcgggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat 5220  
 25 cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgc 5280  
 tttctgtgac tgggtgagta tcaaccaagt cattctgaga atagtgtatg cggcgaccga 5340  
 gttgctcttg cccggcgctc acacgggata ataccgcgcc acatagcaga actttaaaag 5400  
 tgcctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttta 5460  
 gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct ttaactttca 5520  
 30 ccagcgtttc tgggtgagca aaaacaggaa cgcaaaaatgc cgcaaaaag ggaataagg 5580  
 cgacacggaa atgttgaata ctcatactct tcttttttca atattattga agcatttatc 5640  
 aggggttattg tctcatgagc ggatacatat ttgaatgtat ttgaaaaat aaacaaatag 5700  
 ggggttcgcg cacttttccc cgaaaagtgc cactgacgt ctaagaaacc attattatca 5760  
 tgacattaac ctataaaaat aggcgtatca cgaggccctt tgccttcaa g 5811

&lt;210&gt; 3

&lt;211&gt; 2005

&lt;212&gt; DNA

40 &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: vHM41

45 &lt;400&gt; 3

agtagaaaca aggggtattt tctttaccta gctaggcctg cgcgcaatta accctcacta 60  
 aagggaacaa aagctggagc tccaccgagg tggcgccgcg tctagcatat gtttttcgtc 120  
 tcagccaate cctctagcat atgtttttcg tctcagccaa tccctctaga agcttcgtac 180  
 50 gcatgcaagc tttaaatgca tatagtgcac cgcattgttc cgtttcttcac acatatgaaa 240  
 acaaggccca ttgcaatggc aagaagcaaa aagcatgatg ccccgaaagt aaaccaaagt 300  
 atcacatttt tgtagccact actcaatttg actgggtcaa ttgtattctt attttgcac 360  
 gcttctcttc tgtatttgc gtgacataaa gtattgttcc ttatactagc catacaatca 420  
 tcgtcacatt tatgaaaaat ttcaaaagcaa ccagtgcctt cctcttcagc attttccctt 480  
 aattgttttc tcactcgtct atacagcttg ttcattctct aatcagccaa atcaatagtg 540  
 55 tgcctgggtt ccattgccc aagaagtcca gcattgtaag accatacttc tgtgatggag 600  
 tctttgggtc agtaatttaa attgccaatc tgcctttcca ctccagtga ttcatattct 660  
 attagctcaa attgctgggt ggtttttctta atgagtctat ttaactttcc ggttatctga 720  
 tcaattgccc attgggtgct tttgtagtct gctgcagttc cttctccttg tgcatctga 780  
 tgcctgaaac cgtaccaccc gtccagcaga ccttcccaac cattttcaat aaaccctgct 840  
 60 atagcaccaa acagggcctt ttttttctt tttttggaag gtccgggaac gttcttcac 900  
 ccagttgcca ataataaact ttcctgtttt acatatcttg ggcatttgc aactgctctg 960



ctattttagt tttgaaaagg caatctgctt gttatagtcc ctccactgtg gttagcattcc 1020  
 ccttcgcaat tagcatcaac ctgcacatcg ctctggatcc ccattggactt tcccctcaag 1080  
 aagctggcac gatttggagc tatgaaagcc ccattgaaac taaaagtaac tgtatcattg 1140  
 ggatccaaga tcaaccaatg aaaaatcaatc cgtccggacc ggccatttat ctggcggtcg 1200  
 5 gttcctggac tcggcacaaa agattgatga tatttggaaac tcccgaactgt tatcagttta 1260  
 tttccactcc catatagttt ggtctgttcg gtggttgatc ctgaatgggtg gattccccag 1320  
 actatcagaq ctgattctct cctctgtttt ttgtatgatc ttgtcatttg tgggaaagaa 1380  
 gcattgtctg tatttgacag gagccactcc atttctgcat agaataaaga ccctgatctt 1440  
 ctacatgcac tagttgttcc gttgttcctt attccactat atgtgaatcc cattgtttct 1500  
 10 ttgtcaatcc caccgatcc tctgaggatt tgtcccaatg cctcttcatt aacaaaacttc 1560  
 cccgggtaac aaacatcatt tcttctctgt cctctgatta ttagatcagc tgaataattct 1620  
 agaaattggc cgcattgagg tggtcggta atggcccta acagtccgca ttggccaaga 1680  
 tcagtgggtt ttttcccttt tgagcaaatc ttggggatgt ttgtccgctc cactgtttcc 1740  
 gttgcattga caacttctac tctctctca gtgagtgtgt ttactttgtt gccatttgat 1800  
 15 acagcatgat gtccaagaca aattttgtct gcatttgttg ggatgactgc cgcaagggtg 1860  
 aaaaccagga ttgtagtgtt cattttggta cctacaatat gtttttcgtc tcagccaatc 1920  
 cctggtacaa tatgtttttc gtctcagcca atccgtgtac gatgtggatg tcaactcagt 1980  
 agtgatttat taccctgctt ttgct 2005

20

<210> 4  
 <211> 1146  
 <212> DNA  
 <213> Artificial Sequence

25

<220>  
 <223> Description of Artificial Sequence: WHM81

<400> 4  
 30 agtagaaaaca aggttatctt tctttacctt gctaggcctg cgcgcaatta accctcacta 60  
 aagggaacaa aagctggagc tccaccgagg tggcgccgc tctagcatat gtttttcgtc 120  
 tcagccaata cctctagcat atgtttttcg tctcagccaa tccctctaga agcttcgtac 180  
 gcatgcttaa ataagctgaa acgagaaaagt tcttatctct tgcctcactt caagcggtag 240  
 ttgtaaggct tgcataaatg ttatttcttc aaaactatct tctgttatct tcaatctatg 300  
 35 tctcacttct tcaattaacc atcttatctt ttcaaatctt tgactcaatt gttctcgcca 360  
 ttttccgtt ctgcttttga gggagtggag gtcccccatt ctccattactg cttctccaag 420  
 cgaatctctg tatagtctca gagactcgaa ctgtgttatt attccattca agtctccga 480  
 tqaggacccc aattgcattt ttgacatcct catcagatgc tccctggaaga gaaggcaatg 540  
 gtgaaatttt gccgacaatt gctccctcat cgggttaaagc ccttaatatg atgagagttt 600  
 40 ccagccgata gaaaatcaca ctgaagtctg ctttcagtar gatgtctctc cccatgatcg 660  
 cctggtccat tctgatgcaa agggagcctg ccactttctg tttgggcatt agcatgaacc 720  
 agtcccttga catctcttca agagtcatgt cagttaggta gcgtgtagca ggtacagagg 780  
 caatgggtcat ttttaagtgc tcatcggaat cgtccctcag aatccgctcc actatctgct 840  
 ttccaacacg agtagctgtg tcatgttcca gaccaagagt gctgcctctt cccctcaggg 900  
 45 acttctgata tcggcgaaat cggtaagga atggggcatc acccaattct tggctctgaa 960  
 atcgtttgag gacatgcca aaaaaagcgt ctacctgaaa gcttgacaca ggttggaat 1020  
 ccattatggt accacaata tgtttttctt ctcagccaat cctggtaca atatgttttt 1080  
 cgtctcagcc aatctctgta cgtgtggat gtccctcagt gattgattat ctaccctgct 1140  
 tttgct 1146

50

<210> 5  
 <211> 5860  
 <212> DNA  
 55 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: pAM424

60

<400> 5  
 cttcgtatttg ctgactgatg agtccgtgag gacgaaacga aaaacatatt gttagagctcg 60

|    |             |             |             |             |             |             |      |
|----|-------------|-------------|-------------|-------------|-------------|-------------|------|
|    | aattcatcga  | aatgaccgac  | caagcgacgc  | csaacctgcc  | atcacgagat  | ttcgattcca  | 120  |
|    | ccqccgcctt  | ctatgaaagg  | ttgggcttcg  | gaatcgtttt  | ccgggacgcc  | ggctggatga  | 180  |
|    | tcctccagcg  | cggggatctc  | atgctggagt  | ttctcggcca  | ccccgggctc  | gatccctcgc  | 240  |
|    | cgagttgggt  | cagctgctgc  | ctgaggctgg  | acgacctcgc  | ggagttctac  | cggcagtgca  | 300  |
| 5  | aatccgtcgg  | catccaggaa  | accagcagcg  | gctatccgcg  | catccatgcc  | cccgaactgc  | 360  |
|    | aggagtgggg  | aggcacgatg  | gccgcttttg  | ccccggatct  | ttgtgaaggga | accttacttc  | 420  |
|    | tgtggtgtga  | cataattgga  | caaactacct  | acagagattt  | aaagctctaa  | ggtaaatata  | 480  |
|    | aaatttttta  | gtgtataatg  | tgttaaacta  | ctgattctaa  | ttgttttgtt  | atttttagatt | 540  |
|    | ccaacctatg  | gaactgatga  | atgggagcag  | tggtggaatg  | cctttaatga  | ggaaaacctg  | 600  |
| 10 | tttggctcag  | aagaaatgcc  | atctagtgtat | gatgaggcta  | ctgctgactc  | tcaacattct  | 660  |
|    | actcctccaa  | aaaagaagag  | aaaggtagaa  | gaccccaagg  | actttccttc  | agaattgcta  | 720  |
|    | agttttttga  | gtcatgtctt  | gttttagtaat | agaactcttg  | cttgctttgc  | tatttacacc  | 780  |
|    | acaaaggaaa  | aagctgcact  | gctatacaag  | aaaattatgg  | aaaaatattc  | tgtaaccttt  | 840  |
|    | ataagtaggc  | ataacagtta  | taactgtttt  | atactgtttt  | ttcttactcc  | acacaggcat  | 900  |
| 15 | agagtgtctg  | ctattaataa  | ctatgctcaa  | aaattgtgta  | ccttttagctt | tttaatttgt  | 960  |
|    | aaaggggtta  | ataaggaata  | tttgatgtat  | agtgccttga  | ctagagatca  | taatcagcca  | 1020 |
|    | taccacattt  | gtagagggtt  | tacttgcttt  | aaaaaacctc  | ccacacctcc  | ccctgaacct  | 1080 |
|    | gaacataaaa  | atgaatgcaa  | ttgttggtgt  | taacttgctt  | attgcagctt  | ataatggtta  | 1140 |
|    | caataaaagc  | aatagcatca  | caaatttcac  | aaataaagca  | tttttttcac  | tgcattctag  | 1200 |
| 20 | ttgtgggttg  | tccaaactca  | tcaatgtatc  | ttatcatgtc  | tggtatccca  | ggaagctcct  | 1260 |
|    | ctgtgtcctc  | ataaacctta  | acctcctcta  | tttgagagga  | cattccaatc  | ataggctgcc  | 1320 |
|    | catccacctc  | ctgtgtcctc  | ctgttaatta  | ggtcacttaa  | caaaaaggaa  | attgggtagg  | 1380 |
|    | ggtttttcac  | agaccgcttt  | ctaagggtta  | ttttaaaata  | tctgggaagt  | cccttccact  | 1440 |
|    | gctgtgttcc  | agaagtgttg  | gtaaacagcc  | cacaaatgtc  | aacagcagaa  | acatacaagc  | 1500 |
| 25 | tgtcagcttt  | gcacaagggc  | ccaacacctc  | gctcatcaag  | aagcactgtg  | gttgcgtgtg  | 1560 |
|    | tagtaatgtg  | caaaacagga  | ggcacatttt  | ccccacctgt  | gtaggttcca  | aaatatctag  | 1620 |
|    | tgttttcatt  | tttacttgga  | tcaggaacct  | agcactccac  | tggtataagca | ttatccttat  | 1680 |
|    | ccaaaacagc  | cttgtgtgtc  | gtgttcactc  | gctgactgtc  | aactgtagca  | ttttttgggg  | 1740 |
|    | ttacagtttg  | agcaggatat  | ttggtcctgt  | agttttgctaa | cacacctgtc  | agctccaaag  | 1800 |
| 30 | gttccccacc  | aacagcaaaa  | aaatgaaaat  | ttgacctgtg  | aatgggtttt  | ccagcaccat  | 1860 |
|    | tttcatgagt  | ttttttgtgtc | cctgaatgca  | agtttaacat  | agcagttacc  | ccaataacct  | 1920 |
|    | cagtttttaac | agtaacagct  | tcccacatca  | aaatatattcc | acagggttaag | tcctcattta  | 1980 |
|    | aattaggcaa  | aggaattctt  | gaagacgaaa  | gggcctcgtg  | atacgcctat  | ttttataggt  | 2040 |
|    | taatgtcatg  | ataataatgg  | tttcttagac  | gtcagggtggc | acttttcggg  | gaaatgtggc  | 2100 |
| 35 | cggaacccct  | atttgtttat  | tttctaaaat  | acattcaaat  | atgtatccgc  | tcattgagaca | 2160 |
|    | ataaacctga  | taaatgcttc  | aataatattg  | aaaaagggaag | agtatgagta  | ttcaacattt  | 2220 |
|    | ccgtgtcgcc  | cttatccctt  | tttttgcggc  | attttgcctt  | cctgtttttg  | ctcaccacaga | 2280 |
|    | aacgctgggtg | aaagtataaag | atgctgaaga  | tcagttgggt  | gcacgagtgg  | gttacatcga  | 2340 |
|    | actggatctc  | aacagcggta  | agatccttga  | gagttttcgc  | cccgaagaac  | gttttccaat  | 2400 |
| 40 | gatgagcact  | tttaaagtcc  | tgctatgttg  | cgcgggtatta | tcccgtgttg  | acgccgggca  | 2460 |
|    | agagcaactc  | ggtcgccgca  | tacactattc  | tcagaatgac  | ttgggtgagt  | actcaccagt  | 2520 |
|    | cacagaaaag  | catcttacgg  | atggcatgac  | agtaagagaa  | ttatgcagtg  | ctgccataac  | 2580 |
|    | catgagtgtat | aacactgcgg  | ccaacttact  | tttgacaacg  | atcggaggac  | cgaaggagct  | 2640 |
|    | aaccgctttt  | ttgcacaaca  | tgggggatca  | tgtaactcgc  | cttgatcgtt  | gggaaccgga  | 2700 |
| 45 | gctgaatgaa  | gccataccaa  | acgacqagcg  | tgacaccacg  | atgcctgcag  | caatggcaac  | 2760 |
|    | aacgtttcgc  | aaactattaa  | ctggcggaact | acttaactcta | gcttcccggc  | aacaattaat  | 2820 |
|    | agactggatg  | gaggcggata  | aagttgcagg  | accacttctg  | cgctcggccc  | ttccggctgg  | 2880 |
|    | ctgggtttat  | gctgataaat  | ctggagccgg  | tgagcgtggg  | tctcgcggta  | tcattgcagc  | 2940 |
|    | actggggcca  | gatggtaagc  | cctcccgtat  | ctgagttatc  | tacacgacgg  | ggagtcaggc  | 3000 |
| 50 | aactatggat  | gaacgaaata  | gacagatcgc  | tgagataggt  | gcctcactga  | ttaagcattg  | 3060 |
|    | gtaactgtca  | gaccaagtct  | actcatatat  | acttttagatt | gattttaaaac | ttcattttta  | 3120 |
|    | attttaaagg  | atctagggtga | agatcccttt  | tgataatctc  | atgacaaaaa  | ttcccttaacg | 3180 |
|    | tgagttttcg  | ttccactgag  | cgtcagaccc  | cgtagaaaaa  | atcaaaggat  | cttcttgaga  | 3240 |
|    | tccttttttt  | ctgcgcgtaa  | tctcctgttt  | gcaaacaaaa  | aaaccaccgc  | taccagcggg  | 3300 |
| 55 | gctttgtttg  | ccggatcaag  | agctaccaac  | tttttttccg  | aaggtaactg  | gcttcagcag  | 3360 |
|    | acgcgagata  | ccaaatactg  | tcttcttagt  | tgagccgtag  | ttagggccacc | acttcaagaa  | 3420 |
|    | ctctgtagca  | ccgcctacat  | acctcgctct  | gctaatectg  | ttaccagtgg  | ctgctgccag  | 3480 |
|    | tggcgataag  | tctgtcttta  | ccgggttgga  | ctcaagacga  | tagttaccgg  | ataaggcgca  | 3540 |
|    | gcggtcgggc  | tgaacggggg  | gttcgtgcac  | acagcccagc  | tcggagcgaa  | cgccttacac  | 3600 |
| 60 | cgaactgaga  | tacctacaac  | gtgagctatg  | agaaaagcgc  | acgcttcccg  | aagggaagaa  | 3660 |
|    | ggcgagacag  | tatccggtaa  | gcggcagggt  | cggaaacagga | gagcgcacga  | gggaagcttc  | 3720 |

```

5  agggggaaac gcttggtatc tttatagtc tgtcgggttt cggcacctct gacttgagcg 3780
   tcqatctttg tgatgctcgt caggggggag gaggctatgg aaaaacgcca gcaacgcggc 3840
   tttttacggg ttcttgccct ttcgctggcc ttttgctcac atgttctttc ctgcgttatc 3900
   ccttgaattct gtggataacc gtattaccgc ctttgagtga gctgataccg ctgcgcgcag 3960
   ccnaacgacc gagegcagcg agtcagttag cgaggaagcg gaagagcgcc tgatgcggtg 4020
   tttttccctt acgcatctgt gcgggtatttc acaccgcata tgggtgcactc tcagtacaat 4080
   ctgctctgat gccgcatagt taagccagta tacactccgc tatcgctacg tgactgggtc 4140
   atggctgccc cccgacaccc gccaacaccc gctgacgcgc cctgacgggc ttgtctgctc 4200
   ccgcatcccg cttacagaca agctgtgacc gtctccggga gctgcatgtg tcagagggtt 4260
10  tcaacgtcat caccgaaacg ccgagggcag ctgtggaatg tgtgtcagtt aggggtggtg 4320
   aaqtcctccag gctcccccag aggcagaagt atgcaaaagc tgcatctcaa ttagtacgca 4380
   accaggtgtg gaaagtcccc aggtctccca gcaggcagaa gtatgcaaag catgcatctc 4440
   aattagtcag caaccatagt cccgccccca actccgcccc tcccggccct aactccgccc 4500
   agttccgccc attctccgcc ccatggctga ctaatttttt ttattttatgc agaggccgag 4560
15  gcggctcggg cctctgagct attccagaag tagtgaggag gcttttttgg aggcctaggc 4620
   ttttgcacaa agcttcacgc tgccgcaagc actcaggggc caagggctgc taaagggaagc 4680
   ggaacacgta gaaagccagt ccgcagaaac ggtgctgacc ccggatgaat gtcagctact 4740
   ggcttatctg gacaaggga aacgcaagcg caaagagaaa gcaggtagct tcagtgggc 4800
   ttacatggcg atagctagac tgggcggttt tatggacagc aagcgaaccg gaattgccag 4860
20  ccggggcgcc ctctggtaag gttgggaagc cctgcaaagt aaactggatg gctttcttgc 4920
   cgcgaaggat ctgatggcgc aggggatcaa gatctgatca agagacagga tgaggatcgt 4980
   ttgcgatgat tgaacaagat ggattgcacg caggttcttc ggccgcttgg gtggagaggc 5040
   ttttgggcta tgactgggca caacagacaa tgggtgctc tgatgccgcc gtgtccggc 5100
   tgcagcgca ggggcccgcg gttctttttt tcaagaccga cctgtccggt gccctgaatg 5160
25  aactgcagga cgaggcagcg cggctatcgt ggctggccac gacggcggtt ccttgccgag 5220
   ctgtgctoga cgttgtcact gaagcgggaa gggactggct gctattgggc gaagtgcgg 5280
   ggcaaggatct cctgtcatct cacttgctc ctgcccagaa agtatccatc atggctgatg 5340
   caatgcggcg gctgcatacg cttgatccgg ctacctgccc attcgaccac caagcgaaac 5400
   atcgcatcga gcgagcacgt actcggatgg aagccggtct tgcgatcag gatgatctgg 5460
30  acgaagagca tcaggggctc gcgccagccg aactgttcgc caggctcaag gcgcgatgc 5520
   ccgacggcga ggatctcgtc gtgacctatg gcgatgctg cttgcccgaat atcatggtgg 5580
   aaaatggccg cttttctgga ttcatcgact gtggccggtt ggggtgtggc gaccgctatc 5640
   aggcacatagc gttggctacc cgtgatattg ctgaagagct tggcggcgaa tgggctgacc 5700
   gcttctcgtc gctttacggt atcgccgctc ccgattcgca gcgcacgccc ttctatcgcc 5760
35  tttctgacga gttcttctga gcgggactct ggggttcgaa tcttaccagg gattggctga 5820
   ttgatgaatc cgtgaggacg aaacgaaaaa ctatggtac 5860

```

```

40  <210> 6
     <211> 4610
     <212> DNA
     <213> Artificial Sequence

```

```

45  <220>
     <223> Description of Artificial Sequence: pHL2507

```

```

   <400> 6
   gaggcatttc agtcagttgc tcaaggtacc aaaatgaaca ctcaaactct ggttttcgcc 60
   cttgcggcag tcattccccc aaatgcagac aaaatttgtc ttggacatca tgctgtatca 120
50  aatggcacca aagtaaacac actcactgag agaggagtag aagttgtcaa tgcaacggaa 180
   acagtggagc ggacaaacat ccccaaaatt tgcctcaaaag ggaaaaaagc cactgatctt 240
   ggccaatgcg gactgttagg gaccattacc ggaccacctc aatgcgacca atttctagaa 300
   ttttcagctg atctaataat cgagagacga gaaggaaatg atgtttgtta cccgggggag 360
   tttgttaatg aagaggcatt gcgacaaatc ctcaagagat cagggtgggtt tgacaaagaa 420
55  acaatgggat tcacatatag tggaaataag accaacggaa caactagtgc atgtagaaga 480
   tcagggtctt cattctatgc agaaatggag tggctcctgt caaatacaga caatgcttct 540
   ttccacaaaa tgacaaaaac atacaaaaaa acagggagag aatcagctct gatagctgtg 600
   ggaattccacc attcaggatc aaccacggaa cagaccaaac tatatgggag tggaaataaa 660
   ctgataaacg tcgggagttc caaatatcat caatcttttg tgccgagtc aggaacacga 720
60  ccgcaataaa atggccgggtc cggacggatt gattttcatt gggtgatctt ggatcccaat 780
   gatacactta ctttttagtt caatggggct ttcatagctc caaatcgtgc cagcttcttg 840

```

aggggaaagt ccatgggggat ccagagcgat gtgcagggtg atgctaattg cgaaggggaa 900  
tgctaccaca gtggaggggac tataacaagc agattgacctt ttcaaaacat aaatagcaga 960  
gcagttggca aatgcccaag atatgtaaaa caggaaaagt tattattggc aactgggatg 1020  
aagaacgttc ccgaaccttc caaaaaaagg ggaagggtctg gctgacgggt ggtacgggtt caggcatcag 1080  
5 gggtttattg aaaatgggtg tgacagcagac tacaaaagca cccaatcggc aattgatcag 1200  
aatgcacaag gagaagggaac actcattaag aaaaccaacc agcaatttga gctaatagat 1260  
ataaccggaa agttaaatag aaagcagatt ggcaatttaa ttaactggac caaagactcc 1320  
aatgaattca ctgaagtggg caatgctgaa ctcttctgtg caatggaaaa ccagcacact 1380  
atcacagaag tatgggtctta gatgaacaag ctgtatgagc gagtggaggaa acaattaagg 1440  
10 attgatttgg ctgattcaga cactgggtgc ttgaaattt ttcataaatg tgacgatgat 1500  
gaaaatgctg aagaggatgg caatacttat gatcacagca aatacagaga agaagcgatg 1560  
tgtatggcta gtataaggaa cccagtcaaa ttgagtagtg gctacaaaga tgtgatactt 1620  
caaaatagaa tacaaattga atgctttttg ctctttggca ttgcaatggg ccttgttttc 1680  
tggtttagct tcggggcctc catgctgtgc actatttcta tataggtttg gaaaaaaaca 1740  
15 atatgtgtga agaacggaaa aggtcgacca gtactccggg cgaaactttg 1800  
ccccctgttt ctactcccc cctggtgggc gaccagatgt ccgaaagtgt ccccccccc 1860  
tttttttttt ttccccgat gctggagggtc ctctggactc tttttttttt tttttttttt 1920  
cccccccccc ggccgggaac ggccggggcca ctctggactc ttggcggatg agagaagatt ttcagcctga 1980  
20 ttttttgggg atcgccgct agcttctgtt ttggcggatg gaatttgcct ggccggcagta 2040  
tacagattaa atcagaacgc agaagcggtc tgataaaaca gaaactgcct gaaacgccgt agcggccgatg 2100  
gcgcggtggt cccacctgac cccatgcccga actcagaagt gaaactgccca ggcatcaaat aaaacgaaag 2160  
gtagtgtggg gtctcccat gcgagagtag ggaactgccca ggcatcaaat cgctctcctg 2220  
gctcagtcga aagactgggc ctctcgtttt atctgttgtt tgctcgtgaa cgtcctcctg 2280  
agttaggaca atccgcccgg agcggatttg aacgttgcca agcaacggcc cggagggtgg 2340  
25 cgggcaggac gcccgccata aactgcccag catcaaatga agcagaaggc catctctgacg 2400  
gatggccttt ttgctttct acaaaactct ttgtttattt ttctaaatac attcaaatat 2460  
gtatccgctc atgagacaat aacctgata aatgcttcaa taatattgaa aaaggaagag 2520  
tatgagtatt caacatttcc gtgtcgccct tttccctttt ttgctggcat ttgctcttc 2580  
30 tgtttttgct caccagaaaa cgctgtgtaa agtaaaagat gctgaagatc agttgggtgc 2640  
acgagtgggt tacatcgaac tggatctcaa cagcggtaag atccttgaga gttttcgccc 2700  
cgaagaacgt ttccaatga tgagcacttt taaagtcttg ctatgtggcg cggattatc 2760  
ccgtgttgac gccgggcaag agcaactcgg tcgccgcata cactattctc agaattgactt 2820  
ggttgagtac tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt 2880  
35 atgcagtact gccataacca tgagtgtata cactgcggcc aacttacttc tgacaacgat 2940  
cggaggagccg aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgctt 3000  
tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat 3060  
gctgttagca atggcaacaa cgttgccgaa actattaact ggcgaaactac ttactctagc 3120  
ttcccgccaa caattaatag actggatgga ggccgataaa gttgcaggac cactctctcg 3180  
40 ctccggccct ccggctggct ggtttatttc tgataaatct ggagccgggtg agcgtgggtg 3240  
tcggcggtat attgcagcac tggggccaga tggtaagccc tcccgatcgt agataggtgc 3300  
cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg tttagattga 3360  
ctcactgatt aagcattggt ttaaaaggat ctaggtaag atcctttttg ataactctat 3420  
45 tttaaaactt catttttaat agttttcgtt ccactgagcg tcagaccccg tagaaaagat 3480  
gaccaaaaac ccttaacgtg ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa 3540  
caaaggatct tcttgagatc tttgttttgc ggtatcaagag ctaccaactc tttttccgaa 3600  
accaccgcta ccagcggtag ttcagcagag cgcagatacc aaataactgc cttctagtgt agccgtagt 3660  
ggtaactggc ttcaagaact ctgtagcacc gcctacatac ctcgctctgc taactctgtt 3720  
agggccaccac gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata 3780  
50 accagtggct aagggcgagc ggtcggggtg aacggggggg tcgtgcacac agcccagctt 3840  
gttacgggat aactacaccg aactgagata cctacagcgt gagctatgag aaagcggcc 3900  
ggagcgaacg accacacagg ccgacaggta tccggtaagc ggcagggtcg gaacaggaga 3960  
ggttcccgaa gggagaaaag cggacaggta cctggtaagc ggcagggtcg tccgggtttcg 4020  
gcgcacgagg gaggcttccag ggggaaacgc ctggtatctt tatagtcctg tccgggtttcg 4080  
ccacctctga cttgagcgtc gatttttjtg atgctcgtca gggggggcgga gcctatggaa 4140  
55 aaacggcagc aacggcgccct ttttacgggt cctggccttt tgctggcctt ttgtctacat 4200  
gttcttttct gcgttatccc ctgattcatt aatgcaggtc acgatccttt ctggcgagtc 4260  
cccggtcgga gtcggagagc gctccctgag cgcgtgcggc ccgagaggtc gcgcctggcc 4320  
ggccttcggt cctcgtgtg tccgggtcgt aggaggggcc ggccgaaaat gcttccggct 4380  
cccgctctgg agacacgggc cggcccccct cgtgtggcac gggcgggccg gaggggcgtc 4440  
60 ccggcccggc gctgtcccgc cgtgtgtcct ggggttgacc agagggcccc gggcgctccg 4500  
ttctgtggcg ccatggtggc gtttttgggg acaggtgttc gtgtccgtgt cgcgcgtcgc

ctggggcggg gggtggtcg gtgacgcgac ctcccgcccc cgggggaggt atatctttcg 4560  
cttcgagtcg gcatttttggg ccgccgggtt attagtagaa acaggggtac 4610

5 <210> 7  
<211> 3558  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence: pHL2583

<400> 7  
tattaqtaga aacaggggat tttttattct agtacattac gccccgccct gccactcacc 60  
15 gcagctactgt tgaatttcac taagcattct gccgacatgg aagccatcac agacggcatg 120  
atgaacctga atcgccagcg gcatcagcac cttgtcgcc tgcgtataat atttggccat 180  
ggtgaaaacg ggggcgaaga agttgtccat attggccacg tttaaatcaa aactggtgaa 240  
actcaccag ggattggctg agacgaaaaa catattctca ataaaccctt tagggaaata 300  
ggccagggtt tcaccgtaac acgccacatc ttgcgaatat atgtgtagaa actgccggaa 360  
20 atcgctcggtg tattcactcc agagcgatga aaacgttca gtttgctcat ggaaaacggg 420  
gtaacaagggt tgaacactat cccatatcac cagctcaccg tctttcattg ccatacggaa 480  
ttcccgatga gcatcctca ggcgggcaag aatgtgaata aaggccggat aaaacttgtg 540  
cttatttttt tttacggctt ttaaaaaggc cgtaatatcc agctgaacgg tctggttata 600  
ggtacattga gcaactgact gaaatgcctc aaaatgtct ttacgatgcc attgggatat 660  
25 atcaacgggt gtatatccag tgatttttt cccatgatt atggccatta ccttgtttc 720  
tactccccc caacttcgga ggtcgaccag tactccgggc gaaactttgt ttttttttt 780  
tccccgatg ctggaggtcg accagatgtc cgaaagtgtc ccccccccc ccccccccg 840  
gcgcggaaag gcggggccac tctggactct ttttttttt ttttttttt tttttggga 900  
tcggccgcta gcttctgttt tggcggtga gagaagattt tcagcctgat acagattaaa 960  
30 tcagaacgca gaagcggtct gataaaacag aatttgctg gcggcagtag cgcggtggtc 1020  
ccacctgacc ccattgccga ctcagaagtg aaacgccgta gcgccgatgg tagtgtggg 1080  
cttccccatg cgagagtagg gaactgccag gcatcaaata aaacgaaagg ctcagtcgaa 1140  
agactgggct tttcgtttta tctgttgttt gtcggtgaac gctctcctga gtaggacaaa 1200  
tcggccggga gcggatttga acgttgcgaa gcaacggccc ggagggtggc gggcaggacg 1260  
35 cccgccataa actgccaggg atcaaatata gcagaaggcc atcctgacgg atggccttt 1320  
tgcgtttcta caaactcttt tgtttatttt tctaaatata tcaaatatg tatccgtca 1380  
tgagacaata accctgataa atgcttcaat aatatgaaa aaggaaagat atgagtattc 1440  
aacatttcgg tctgcctctt attccttttt ttgcggcatt ttgccttctt gtttttgctc 1500  
acccagaaac gctcgtgaaa gtaaaagatg ctgaagatca gtcgggtgca cgagtgggtt 1560  
40 acatcgaaat ggatctcaac agcggtaaga tccctgagag ttttcgcccc gaagaacgtt 1620  
ttccaatgat gagcactttt aaagtctctg catgtggcgc ggtattatcc cgtgttgacg 1680  
ccgggcaaga gcaactcggc cgcgcgatac atattctca gaatgacttg gttgagtact 1740  
caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta tgcagtgtc 1800  
ccataaccaat gagtataaac actgcggcca acttacttct gacaacgata ggaggaccga 1860  
45 aggagctaac cgtttttttg cacaacatgg gggatcatgt aactcgcctt gatcgttggg 1920  
aacggagctt gaatgaagcc atacaaaacg acgagcgtga caccacgat cctgtagcaa 1980  
tggaacaaac gttgcgcaaa ctattaactg qcgaactact tactctagct tccgggcaac 2040  
aattaataga ctggatggag gcggataaag ttccaggacc acttctgcgc tcggcccttc 2100  
cggtcggctg gtttatttgc gataaatctg gagccgggtg gcgtgggtct cgcggtatca 2160  
50 ttgcagcaat ggggccagat ggtaaagccc cccgtatcgt agttatctac acgacgggga 2220  
gtcaggcaac tatggatgaa cgaatatagc agatcgctga gataggtgcc tcatgatta 2280  
agcattggta actgtcagac caagtcttact catatatact tttagattgat ttaaaacttc 2340  
atttttaatt taaaaggatc taggtgaaga tcttttttga taatctcatg accaaaatcc 2400  
cttaacgtga gttttcgttc cactgagcgt caqaccccg agaaaagatc aaaggatctt 2460  
55 cttgagatcc tttttttttg cgtgtaactt gctgcttgca aacaaaaaaa ccaccgctac 2520  
cagcgggtgt ttgtttgccc gatcaagagc ttctaagtga gccgtagtta ggcaccact 2580  
tcagcagagc gcagatacca aatactgtcc tcttagtga gccgtagtta ggcaccact 2640  
tcaagaactc ttagcaccg cctacatacc tcgctctgct aatcctgtta ccagtggctg 2700  
ctgccagtcg cgataagtcg tctcttaccg ggttgactc aagacgatag ttaccggata 2760  
60 aggcgcagcg gtcgggctga acgggggggt cgtgcacaca gccagcttg gacgcaacga 2820  
cttacaccga actgagatac ctacagcgtg agctatgaga aagcgccacg cttcccgaa 2880

|    |   |             |             |            |             |            |      |
|----|---|-------------|-------------|------------|-------------|------------|------|
|    | ggagaaaggc  | ggacaggtat  | ccggtaaagc  | gcagggtcgg | aacaggagag  | cgcacgagg  | 2940 |
|    | agcttccagg  | gggaaacgcc  | tggtatcttt  | atagtcctgt | cgggtttcgc  | cacctctgac | 3000 |
|    | ttgagcgtcg  | atttttgtga  | tgctcgtcag  | gggggcggag | cctatggaaa  | aacgccagca | 3060 |
|    | acqcgccctt  | tttacgggtc  | ctggcctttt  | gctggccttt | tgcttacatg  | ttctttcctg | 3120 |
| 5  | cgttatcccc  | tgattcatta  | atgcagggtc  | cgatcctttc | tggcgagtc   | ccgtgcggag | 3180 |
|    | tcggagagcg  | ctccctgagc  | gcgtgcggcc  | cgagaggtcg | cgcctggccg  | gccttcggtc | 3240 |
|    | cctcgtgtgt  | cccggtcgta  | ggagggggcg  | gccgaaaatg | cttcgggtc   | ccgtcttga  | 3300 |
|    | gacacggggc  | ggccccctgc  | gtgtggcacg  | ggcgcccggg | agggcgctcc  | cgccccggcg | 3360 |
|    | ctgctcccg   | gtgtgtcctg  | gggttgacca  | gagggccccc | ggcgctccgt  | gtgtggctgc | 3420 |
| 10 | gatggtggcg  | tttttgggga  | cagggtgtcc  | tgctcgtgtc | gcgcgtcgcc  | tgggccggcg | 3480 |
|    | gcgtggtcg   | tgacgcgacc  | tcccgccccc  | gggggaggtg | tatctttcgc  | tccgagtcgg | 3540 |
|    | cattttgggc  | cgccgggt    |             |            |             |            | 3558 |
| 15 | <210> #   |             |             |            |             |            |      |
|    | <211> 4342  |             |             |            |             |            |      |
|    | <212> DNA   |             |             |            |             |            |      |
|    | <213> Artificial Sequence                         |             |             |            |             |            |      |
| 20 | <220>   |             |             |            |             |            |      |
|    | <223> Description of Artificial Sequence: pHL2989 |             |             |            |             |            |      |
|    | <400> #   |             |             |            |             |            |      |
| 25 | ctttctggcg  | agtcctccgtg | cggagtcgga  | gagcgtctcc | tgagcgcgtg  | cggcccgaga | 60   |
|    | ggtcgcgcct  | ggccggccctt | cggtccctcg  | tgtgtcccg  | tcgtaggagg  | ggccggccga | 120  |
|    | aaatgcttcc  | ggctcccgct  | ctggagacac  | ggcccgcccc | cctgcgtgtg  | gcacggggcg | 180  |
|    | ccgggagggc  | gtccccggcc  | cggcgtcgtc  | cccgctgtgt | tcctgggggt  | gaccagaggg | 240  |
|    | ccccggggcg  | tcctgtgtgt  | gctgcgatgg  | tgccgttttt | ggggacaggt  | gtccgtgtcc | 300  |
|    | gtgtcgcgcg  | tcgcctgggc  | cggcggcggt  | gtcggtgacg | cgacctcccg  | gccccggggg | 360  |
| 30 | aggatatctt  | ttcgctccga  | gtcggcattt  | tgggccggcc | ggttattagt  | agaaacagg  | 420  |
|    | tattttttat  | actagtaagc  | tcgaaggagt  | ccaccatgag | taaaggagaa  | gaacttttca | 480  |
|    | ctggagttgt  | cccaattctt  | gttgaattag  | atggtgatgt | taatgggcac  | aaattttctg | 540  |
|    | tcagtggaga  | gggtgaaggt  | gatgcaacat  | acggaaaact | taccttataa  | tttacttgca | 600  |
|    | tacttgaaaa  | actacctgtt  | ccatggccaa  | cacttgccac | tactttcact  | tatggtgttc | 660  |
| 35 | aatgcttttc  | aagataccca  | gatcatatga  | aacagcatga | ctttttcaag  | agtgccatgc | 720  |
|    | ccgaagggtt  | tgtacaggaa  | agaactatat  | ttttcaaaag | tgacgggaac  | tacaagacac | 780  |
|    | gtgctgaagt  | caagtttgaa  | ggtgatcccc  | ttgttaatag | aatcgagtta  | aaaggtattg | 840  |
|    | atttttaaga  | agatggaaa   | attcttggac  | acaaattgga | atacaactat  | aactcacaca | 900  |
|    | atgtatacat  | catggctgac  | aagcagaaga  | acggaatcaa | ggccaacttc  | aagaccgcgc | 960  |
| 40 | acaacatcga  | ggacggcgcc  | gtgcagctgg  | cgaccacta  | ccagcagaac  | accccaattg | 1020 |
|    | gcgatggccc  | tgtcctttta  | ccagacaacc  | attacctgtc | cacacaattc  | gccctttcga | 1080 |
|    | aagatcccaa  | cgaaaagaga  | gaccacatgg  | tcctttctga | gtttgtaaca  | gctgctggga | 1140 |
|    | ttacacatgg  | catggatgaa  | ctatacaagg  | gatcccatca | ccatcaccat  | cactaagctc | 1200 |
|    | catggtctag  | atatctagta  | cattacqccc  | cgccttgcca | ctcatcgag   | tactgttgta | 1260 |
| 45 | attcatttaag                                       | cattctgcgc  | acatggaagc  | catcacagac | ggcatgatga  | acctgaatcg | 1320 |
|    | ccagcggcat  | cagcaccttt  | tcgccttgcg  | tataatattt | gcccattggt  | aaaacggggg | 1380 |
|    | cgaagaagtt  | gtccatattg  | gccacgttta  | aatcaaaact | ggtgaaactc  | acccagggat | 1440 |
|    | tggcactcac  | aaagaacatg  | ttctcgatga  | atccttttag | gaagtaggce  | aggttttcac | 1500 |
|    | cgtaacacgc  | cacatcttgc  | gaatatatct  | gtagaaactg | ccggaaatcg  | tcgtggtatt | 1560 |
| 50 | cactccagag  | cgatgaaaac  | gtttcagttt  | gctcatggaa | aacggtgtaa  | caagggtgaa | 1620 |
|    | cactatccca  | tatcaccagc  | tcacgcctct  | tcattgccat | acggaattcc  | ggatgagcat | 1680 |
|    | tcacagggcg  | ggcaagaatg  | tgaataaagg  | ccggataaaa | cttgtgctta  | tttttcttta | 1740 |
|    | cggtctttta  | aaagggcgta  | atatacagct  | gaacgggtct | gttataggta  | cattgagcaa | 1800 |
|    | ctgactgaaa  | tgcttcaaaa  | tgctctttac  | gatgccattg | ggatatatca  | acgggtggat | 1860 |
| 55 | atccagtgat  | ttttttctcc  | atgattatgc  | aaaaaatacc | cttgctttta  | ctccccccca | 1920 |
|    | acttcggagg  | tcgaccagta  | ctccgggcga  | aaactttggt | tttttttttc  | ccccgatgct | 1980 |
|    | ggagggtcgac                                       | cagatgtccg  | aaagtgtccc  | cccccccccc | ccccccgggc  | gcggaacggc | 2040 |
|    | ggggccactc  | tggactcttt  | tttttttttt  | tttttttttt | tttggggatc  | ggccgctagc | 2100 |
|    | ttctgttttg  | gcggatgaga  | gaagattttc  | agcctgatac | agatcaaatc  | agaacgcaga | 2160 |
| 60 | agcgggtctga                                       | taaaacagaa  | tttgccctggc | ggcagtagcg | cgggtggtccc | acctgacccc | 2220 |
|    | atgccgaact  | cagaagtga   | acgcctgacg  | gccgatggta | gtgtgggggtc | tccccatgcg | 2280 |

```

agagtaggga actgccaggc atcaaaataaa acgaaaaggc cagtcgaaaag actgggcctt 2340
tcgtttttatc tgttgtttgt cgggtgaacgc tctcctgagt aggacaaatc cggcgggagc 2400
ggatttgaac gttgcgaagc aacggcccgg aggggtggcg gcaggacgcc cgccataaac 2460
tgccaggcat caaattaaagc agaaggccat cctgacggat ggcttttttg cgtttctaca 2520
5 aaactctttt tttatttttc taaatacatt caaatatgta tccgctcatg agacaataac 2580
cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa catttccgtg 2640
tcgcccttat tccctttttt gcggcatttt gccctcctgt ttttgctcac ccagaaacgc 2700
tggtgaaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac atcgaactgg 2760
atctcaacag cggtaagatc cttgagagtt ttcccccga agaactgttt ccaatgatga 2820
10 gcacttttaa agttctgcta tgtggcgcg cttatccccg tgttgacgcc gggcaagagc 2880
aaactgggtcg ccgcatacac tattctcaga atgacttggg tgagtactca ccagtcacag 2940
aaaagcatct tacggatggc atgacagtaa gagaattatg cagtgtctgc ataaccatga 3000
gtgataacac tgcggccaac ttacttctga caacgatcgg aggaccgaag gagctaaccg 3060
cttttttgca caacatgggg gatcatgtaa ctgccttga tcgttgggaa ccggagctga 3120
15 atgaagccat accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg gcaacaacgt 3180
tgcgcaaaact attaaactggc gaactactta ctctagcttc ccggcaacaa ttaatagact 3240
ggatggaggc ggataaaagt gcaggaccac ttctgcgttc ggcccttccg gctggctggg 3300
ttattgctga taaatctgga gccggtgagc gtgggtctcg cggtatcatt gcagcactgg 3360
ggccagatgg taagccctcc cgtatcgtag ttatctacac gacggggagt caggcaacta 3420
20 tggatgaacg aaatagacag atcgttgaga taggtgcctc actgattaag cattggtaac 3480
tgtcagacca agtttactca tatatacttt agattgattt aaaacttcat ttttaattta 3540
aaaggatcta ggtgaagatc ctttttgata atctcatgac caaaatccct taacgtgagt 3600
tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt 3660
ttttctgccc cgtaatctgc tgccttgcaaa caaaaaaac accgctacca gcgggtggtt 3720
25 gtttgccggg tcaagagcta ccaactcttt ttccgaagg aactggcttc agcagagcgc 3780
agataccaaa tactgtcctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg 3840
tagcacccgc tacataacct gctctgctaa tctgttacc agtggctgct gccagtggcg 3900
ataagtctgt tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcgg 3960
cgggctgaac ggggggttcg tgcacacagc ccagcttgga gcgaacgacc tacacegaac 4020
30 tgagatacct acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg 4080
acaggtatcc ggtaagcggc agggctcgaa caggagagcg cagcagggag cttccagggg 4140
gaaacgcctg gtatctttat agtctgtcgg ggtttcgcca cctctgactt gagcgtcgat 4200
ttttgtgatg ctgctcaggg gggcggagcc tatggaaaaa cgccagcaac gcggcctttt 4260
tacggttcct ggcccttttc tggccttttg ctacatggt ttttctgcg ttatccctg 4320
35 attcattaat gcaggctcac atc

```

&lt;210&gt; 9

&lt;211&gt; 3888

40 &lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: pHL1920

45

&lt;400&gt; 9

```

ccccaaaaaa aaaaaaaaaa aaaaaaaaaa agtccagagt ggccccgccg ttccgcgccg 60
gggggggggg gggggggggg cactttcgga catctggctg acctccagca tcgggggaaa 120
aaaaaaaaaa aaagttttcg ccggagtact ggtcgacctc cgaagtggg ggggagtaga 180
50 aacagggtag ataatacttc actgagtga atccacatcg cgacgcgcgc taatacgaact 240
cactataggg cgaattgggt accgggcccc ccttcgaggc cgacgggtatc gataagcttc 300
gacgagatat tcaggagcta aggaagctaa aatggagaaa aaaatcactg gatataccac 360
cgttgatata tccaatggc atcgtaaaga acattttgag gcatttcagt cagttgtctca 420
ctgtacctat aaccagaccg ttacagctga tattacggcc tttttaaaga ccgtaaaaga 480
55 aaataaagca aggttttacc cggcctttat tcacattctt gcccgctga tgaatgctca 540
tccggaatcc cgtatggcaa tgaaagacgg tgagctgggt atatgggata gtgttcaccc 600
ttgttacacc gttttccatg agcaaaactga aacgttttca tcgctctgga gtgaatacca 660
cgacgatttc cggcagtttc tacacatata ttccgaagat gtggcggtgt acggtgaaaa 720
cgtggcctat ttccctaaag ggtttattga gaatatgtt ttctgtctcag ccaatccctg 780
60 ggtgagtttc accagttttg atttaaacgt ggccaatat gacaacttct tcgccccctg 840
tttaccatg cggaaatatt atacgcaagg ccacaagggt ctgatgccgc tggcgattca 900

```

```

5  ggttcacat ggcgtttgtg atggcctcca tgtcggcaga atgcttaatg aattacaaca 960
   gtactgcgat gagtggcagg gcggggcgta atttttttaa ggcagttatt ggtgccctta 1020
   aacgcctggt gctacgcctg aataagtgat aataagcgga tgaatggcag aaattcgtcg 1080
   aagcctgata tcgaattcct gcagcccggg ggatccacta gttctagagc ggccgccacc 1140
   gcggtggagc tccagctttt gttcccttta gtgagggtta attgcgcgca ggccctagcta 1200
   ggtaaagaaa aatacccttg attcttctaa taaccggcg gcccataatg ccgactcgga 1260
   gcgaaagata tacctcccc gggggcggga ggtcgcgtca ccgaccacgc cgccggccca 1320
   ggcgacgcgc gacacggaca cctgtcccca aaaacgccac catcgcagcc acacacggag 1380
   gcccgcgggc cctctggtca accccaggac acacgcggga gcagcgccgg gccggggacg 1440
   cctcccggc cgcccggtgc acacgcaggg gcccggcccc tgtctccaga gcgggagccg 1500
   gaaacatttt cgcccgcccc ctctacgac cgggacacac gagggaccga agggccggca 1560
   gcgcgcgacc ctccggccgc acgcgcgctc agggagcgct ctccgactcc gcacggggac 1620
   tcgcagaaaa ggatcgtgac ctgcattaat gaatcagggg ataacgcagg aaagaacatg 1680
   tgagcaaaa ggcagcaaaa ggcaggaac cgtaaaaagg ccgcgttgct ggcgtttttc 1740
   cataggctcc gccccctga ctagcatcac aaaaatcgac gctcaagtca gagggtggcg 1800
   aaccgcagac gactataaag ataccaggcg tttccctcg gaagctccct cgtgcgctct 1860
   cctgttcoga cctgcgcgt taccggatac ctgtccgct tctctccctc gggagcggtg 1920
   gcgttttctc atagctcac ctgtagggtat ctcagttcgg tgtaggtcgt tcgctccaag 1980
   ctgggctgtg tgcacgaacc ccccgctcag cccgaccgct gcgccttatc cggttaactat 2040
   cgtcttgagt ccaaccgggt aagacacgac ttatcgccac tggcagcagc cactggtaac 2100
   aqgattagca gacgcaggta tgtaggcggt gctacagagt tcttgaagt gtggcctaac 2160
   tccggttaca ctagaaggac agtatcttgt atctgcgtc tgcgtgaagc agttacctc 2220
   gcaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cgggtggttt 2280
   tttgttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc 2340
   tttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggt tttggctatg 2400
   agattatcaa aaaggatctt cacctagatc cttttaaat aaaaatgaag ttttaaatca 2460
   atctaagta tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca 2520
   cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag 2580
   ataactacga tacgggaggg cttaccatct ggcccagtg ctgcaatgat accgcgagac 2640
   ccacgcctac cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc 2700
   agaagtggct ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct 2760
   agagtgaagta gttcgccagt taatagtgtg cgcaacgttg ttgccattgc tacaggtatc 2820
   gagggtgcac gtcgctcgtt tggatggct tcattcagct ccggttccca acgatcaagg 2880
   cgagttacat gatcccccac gttgtgcaaa aaagcggtta gctccttcgg tccctcgatc 2940
   gttgtcagaa gtaagtggc cgcagtgtta tcaactcatg ttatggcagc actgcataat 3000
   tctcttactg tcatgccatc cgtaaagtgc tttctgtga ctggtgagta ctcaaccaag 3060
   tcatcttgag aatagtgtat gcggcgaccg agttgctctt gcccggcgtc aacacgggat 3120
   aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg tctctcgggg 3180
   cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca 3240
   ccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga 3300
   aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc 3360
   ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata 3420
   tttgaatgta tttagaaaaa taacaaaaag agttttaga aacgaaaaa ggccatccgt 3480
   caggatggcc tttctgctta tttgatgcct ggcagtttat ggccggcgct ctgcccgcca 3540
   cctcccgggc cgttgcttcg caacgttcaa atccgctccc ggccgatttg tccactcag 3600
   gagagcgttc accgacaaac aacagataaa acgaaaggcc cagtccttcg actgagcctt 3660
   tctttttat tgatgcctgg cagttcccta ctctgcagtg gggagacccc acactaccat 3720
   cggcgctacg gcgtttcact tctgagttcg gcatggggtc aggtgggacc accgcgctac 3780
   tgcgcgacg caaattctgt tttatcagac cgcttctgcg tctgattta atctgtatca 3840
50 ggcgtgaaaat cttctctcat ccgcaaaaac agaagctagc ggccgatc 3888

```

&lt;210&gt; 10

&lt;211&gt; 12

55 &lt;212&gt; RNA

&lt;213&gt; Influenza A virus

&lt;400&gt; 10

cduccuuuug cu

12

60



5     <210> 11  
      <211> 12  
      <212> RNA  
      <213> Influenza B virus  
      <400> 11  
          nnygcuucug cu 12

10    <210> 12  
      <211> 12  
      <212> RNA  
      <213> Influenza C virus

15    <400> 12  
      ccugcuucug cu 12

20    <210> 13  
      <211> 12  
      <212> RNA  
      <213> Artificial Sequence

25    <220>  
      <223> Description of Artificial Sequence: Modified  
          influenza A 3' sequence (pHL1104 and 1920)

30    <400> 13  
      ccuguuucua cu 12

35    <210> 14  
      <211> 12  
      <212> RNA  
      <213> Artificial Sequence

40    <220>  
      <223> Description of Artificial Sequence: Modified  
          influenza A 3' sequence (pHL1948)

45    <400> 14  
      ccucguucub cu 12

50    <210> 15  
      <211> 13  
      <212> RNA  
      <213> Artificial Sequence

55    <220>  
      <223> Description of Artificial Sequence: Modified  
          influenza A 5' sequence (pHL1920)

60    <400> 15  
      aqaagaauca agg 13

65    <210> 15  
      <211> 13  
      <212> RNA  
      <213> Influenza A virus

<400> 16  
aguagaaaca agg 13

5  
<210> 17  
<211> 13  
<212> RNA  
<213> Influenza B virus

10  
<400> 17  
aguagwaaca rnn 13

15  
<210> 19  
<211> 13  
<212> RNA  
<213> Influenza C virus

20  
<400> 18  
agcaguagca agr 13

25  
<210> 19  
<211> 21  
<212> RNA  
<213> Influenza A virus

30  
<400> 19  
aguagaaaca aggnnnuuuu u 21

35  
<210> 20  
<211> 21  
<212> RNA  
<213> Artificial Sequence

40  
<220>  
<223> Description of Artificial Sequence: Modified  
influenza A 5'-sequence (pHL1920)

<400> 20  
agaagaauca aggnnnuuuu u 21

45  
<210> 21  
<211> 21  
<212> RNA  
<213> Influenza B virus

50  
<400> 21  
aguagwaaca rnnnnnnuuuu u 21

55  
<210> 22  
<211> 19  
<212> RNA  
<213> Artificial Sequence

60  
<220>  
<223> Description of Artificial Sequence: Modified

influenza C 5' sequence

5      <400> 22  
aguaguaaca agrguuuuu      19

10      <210> 23  
         <211> 15  
         <212> RNA  
         <213> Artificial Sequence

15      <220>  
         <223> Description of Artificial Sequence: Modified  
                 influenza A 3' sequence (pHL1104 and 1920)

         <400> 23  
         nnnccucuuu cuacu      15

20      <210> 24  
         <211> 15  
         <212> RNA  
         <213> Artificial Sequence

25      <220>  
         <223> Description of Artificial Sequence: Modified  
                 influenza A 3' sequence (pHL1948)

30      <400> 24  
         nnnccucguu cuccu      15

35      <210> 25  
         <211> 15  
         <212> RNA  
         <213> Artificial Sequence

40      <220>  
         <223> Description of Artificial Sequence: Modified  
                 influenza B 3' sequence

         <400> 25  
         nnnnnyguuu cuacu      15

45      <210> 26  
         <211> 14  
         <212> RNA  
         <213> Artificial Sequence

50      <220>  
         <223> Description of Artificial Sequence: Modified  
                 influenza C 3' sequence

55      <400> 26  
         ccccuuuuu uacu      14

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/01903

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/86 C12N7/01 C12N5/10 A61K39/00 A61K39/145  
A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No      |
|----------|--|---------------------------|
| Y        | DE 197 09 512 A (HOBOM GERD PROF DR DR)<br>10 September 1998 (1998-09-10)<br><br>the whole document<br>---   | 1.4.5.<br>12.14.<br>18-33 |
| Y        | WO 91 03552 A (SINAI SCHOOL MEDICINE)<br>21 March 1991 (1991-03-21)<br><br>figure 11; example 7<br>---   | 1.4.5.<br>12.14.<br>18-33 |
| Y        | TAKASE H. ET AL: "Antibody responses and<br>protection in mice immunized orally<br>against influenza virus."<br>VACCINE.<br>vol. 14, no. 17/18, 1996, pages 1651-1656.<br>XP002110225<br>page 1652, left-hand column, paragraph 1<br>--- | 27                        |
|          | ---<br>-/--  |                           |

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex

## Special categories of cited documents

- A document defining the general state of the art which is not considered to be of particular relevance
- E earlier document but published on or after the international filing date
- L document which may throw doubts on priority claims in which is cited to establish the publication date of another publication or other special reason as specified
- C document referring to an oral disclosure, use, exhibition or other means
- P document published prior to the international filing date but later than the priority date claimed

- document published after the international filing date or priority date and not in contact with the application but cited to understand the principle or theory underlying the invention
- document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- document member of the same patent family

Date of the actual completion of the international search

15 June 2000

Date of mailing of the international search report

07/07/2000

Name and mailing address of the ISA

European Patent Office P.O. Box 1  
7030 Leidschendam  
The Netherlands  
Tel. +31-70-340-2245, Telex 314514 esp  
Fax +31-70-340-3016

Authorized officer

Mandl, B

Form PCT/ISA 210 (second sheet) July 1997

## INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/EP 00/01903

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |  |                      |
|--|--|----------------------|
| Category   | Citation of document, with indication where appropriate, of the relevant passages  | Relevant to claim No |
| A  | ZHOU Y. ET AL.: "Membrane-anchored incorporation of a foreign protein in recombinant Influenza virions."<br>VIROLOGY,<br>vol. 246, 20 June 1998 (1998-06-20), pages 83-94. XP002110226<br>the whole document   | 5                    |
| A  | ZOBEL A. ET AL.: "RNA polymerase I catalysed transcription of insert viral cDNA."<br>NUCLEIC ACIDS RESEARCH,<br>vol. 21, no. 16, 1993, pages 3607-3614. XP002110227<br>page 3607, right-hand column, paragraph 2<br>page 3612, right-hand column, paragraph 2<br>page 3613, left-hand column, line 1<br>page 3614, left-hand column, paragraph 2 | 15-17                |
| A  | WO 96 10641 A (BAYER AG; HOBOM GERD (DE); NEUMANN GABRIELE (DE); MENKE ANNETTE (D))<br>11 April 1996 (1996-04-11)<br>cited in the application<br>the whole document  | 6-11                 |
| A  | FLICK R. ET AL.: "Promoter elements in the influenza vRNA terminal structure."<br>RNA,<br>vol. 2, no. 10, 1996, pages 1046-1057. XP000914725<br>ISSN: 1355-8382<br>the whole document  | 6-11                 |
| A  | NEUMANN G. AND HOBOM G.: "Mutational analysis of influenza virus promoter elements in vivo."<br>JOURNAL OF GENERAL VIROLOGY 1995,<br>vol. 76, no. 7, 1995, pages 1709-1717. XP002140118<br>ISSN: 0022-1317<br>cited in the application   | 6-11                 |
| A  | PICCONE M. E. ET AL.: "MUTATIONAL ANALYSIS OF THE INFLUENZA VIRUS vRNA PROMOTER"<br>VIRUS RESEARCH,<br>vol. 28, no. 2,<br>1 January 1993 (1993-01-01), pages 99-112. XP000619019<br>ISSN: 0168-1702<br>the whole document  | 6-11                 |

-/--

Form PCT/ISA 210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/EP 00/01903

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category: Citation of document with indication, where appropriate, of the relevant passages Relevant to claim No.

|     |   |                                     |
|-----|---|-------------------------------------|
| A   | PALESE P. ET AL.: "Negative-strand RNA viruses: Genetic engineering and applications."<br>PROC. NATL. ACAD. SCI. U.S.A.,<br>vol. 93, October 1996 (1996-10), pages<br>11354-11358, XP000196755<br>page 11354, right-hand column, last<br>paragraph -page 11356, right-hand column,<br>paragraph F | 5                                   |
| P.X | NEUMANN G. ET AL.: "Plasmid-driven<br>formation of influenza virus-like<br>particles."<br>JOURNAL OF VIROLOGY,<br>vol. 74, no. 1, January 2000 (2000-01),<br>pages 547-551, XP002140119<br>ISSN: 0022-538X<br>the whole document  | 1.3-5.<br>12.<br>18-23.<br>25-31.33 |
| P.A | FLICK R. AND HOBOM G.: "Interaction of<br>influenza virus polymerase with viral RNA<br>in the 'corkscrew' conformation."<br>JOURNAL OF GENERAL VIROLOGY,<br>vol. 80, no. 10, October 1999 (1999-10),<br>pages 2565-2572, XP002140120<br>ISSN: 0022-1317<br>figure 1                               | 7-11                                |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 00/01903

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---------------------|--|--|
| DE 19709512 A                             | 10-09-1998          | NONE   |  |
| WO 9103552 A                              | 21-03-1991          | US 5166057 A<br>AT 126272 T<br>AU 636916 B<br>AU 6411890 A<br>CA 2065245 A<br>DE 69021575 D<br>DE 69021575 T<br>DK 490972 T<br>EP 0490972 A<br>ES 2075901 T<br>GR 90100639 A<br>JP 5500607 T<br>PT 95124 A<br>US 5252289 A<br>US 6001634 A<br>US 5578473 A<br>US 5854037 A<br>US 5840520 A<br>US 5786199 A<br>US 5820871 A<br>ZA 9006852 A | 24-11-1992<br>15-08-1995<br>13-05-1993<br>08-04-1991<br>01-03-1991<br>14-09-1995<br>14-12-1995<br>30-10-1995<br>24-06-1992<br>16-10-1995<br>30-12-1991<br>12-02-1993<br>18-04-1991<br>12-10-1993<br>14-12-1999<br>26-11-1996<br>29-12-1998<br>24-11-1998<br>28-07-1998<br>13-10-1998<br>31-07-1991 |
| WO 9610641 A                              | 11-04-1996          | EP 0704533 A<br>AU 3607695 A<br>EP 0783586 A<br>FI 971272 A<br>NZ 293600 A   | 03-04-1996<br>26-04-1996<br>16-07-1997<br>26-05-1997<br>28-01-1999   |

Form 101 (3A) (2000) (patent family members) (July 1992)

**THIS PAGE BLANK (USPTO)**